

A

09/15/99  
JCS60 U.S. PRO

☒ NEW PATENT APPLICATION  
☐ CONTINUATION-IN-PART  
☐ DIVISIONAL

ASSISTANT COMMISSIONER  
FOR PATENTS  
Box Patent Application  
Washington, D.C. 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NO. EL382208277US  
DATE OF DEPOSIT 9/15/99 I HEREBY  
CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED  
STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE"  
SERVICE UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON,  
D.C. 20231  
Mikhail Bayley  
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)  
Mikhail Bayley  
SIGNATURE OF PERSON MAILING PAPER OR FEE

Sir:

Transmitted herewith for filing is the new patent application of:

Inventor: Jean-Pierre Issa

For: **CACNA1G POLYNUCLEOTIDE POLYPEPTIDE AND METHODS OF USE  
THEREFOR**

Enclosed are:

- ☒ 75 pages of the Specification, which includes 5 pages of the claims; and 1 page of the Abstract;  
☐ 11 sheets of drawing(s) ☐ Formal; ☒ Informal;  
☐ An assignment of the invention to \_\_\_\_\_;  
☒ An unsigned Declaration;  
☐ Power of Attorney By Assignee; and  
☐ A verified statement to establish small entity status under 37 C.F.R. 1.9 and 37 C.F.R. 1.27.

JCS60 U.S. PRO  
09/30/99

|                             |   |  |                           |
|-----------------------------|---|--|---------------------------|
| FULL NAME OF FIRST INVENTOR | LAST NAME:<br><b>Issa</b>                       | FIRST NAME:<br><b>Jean-Pierre</b>      | MIDDLE NAME:              |
| CITIZENSHIP                 | STATE OR FOREIGN COUNTRY: <b>Lebanon</b>        |  |                           |
| POST OFFICE ADDRESS         | POST OFFICE ADDRESS:<br><b>100 Welford Road</b> | CITY AND STATE:<br><b>Timonium, MD</b> | ZIP CODE:<br><b>21231</b> |

The filing fee has been calculated as shown below:

In re Application of:  
Jean-Pierre Issa  
Application No.: Unassigned  
Filed: September 15, 1999  
Page 2


PATENT  
Attorney Docket No.: JHU1590

| For  | Number<br>Filed |   | Number<br>Extra |   | Rate         |              | Fee             |                 |
|--|-----------------|---|-----------------|---|--------------|--------------|-----------------|-----------------|
|  |                 |   |                 |   | Small Entity | Other Entity | Small<br>Entity | Other<br>Entity |
| Total Claims   | 32              | = | 12              | X | \$9          | \$18         | =               | \$ \$           |
| Independent Claims                                       | 6               | = | 3               | X | \$39         | \$78         | =               | \$ \$           |
| Multiple Dependent<br>Claims Presented: ___ Yes ___X_ No |                 |   |                 |   | \$135        | \$270        |                 | 0               |
| BASIC FEE  |                 |   |                 |   | \$380        | \$760        |                 | \$ \$           |
|  |                 |   |                 |   | TOTAL FEE    |              |                 | \$ \$           |

- ☒ The payment of the filing fee is to be deferred until the Declaration is filed. Do not charge our deposit account.
- \_\_\_ The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1895. A duplicate copy of this sheet is enclosed.
- \_\_\_ Any additional filing fees required under 37 C.F.R. 1.16.
- \_\_\_ Any patent application processing fees under 37 C.F.R. 1.17.

Respectfully submitted,

Date: 9/15/99

  
Lisa A. Haile  
Attorney for Applicant  
Registration No. 38,347  
Telephone: 858-677-1456  
Facsimile: 858-677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1600  
San Diego, CA 92121-2189

|   |                      |
|---|----------------------|
| CERTIFICATE OF MAILING BY "EXPRESS MAIL"  |                      |
| EXPRESS MAIL LABEL NUMBER   | <u>EL382208277US</u> |
| DATE OF DEPOSIT   | <u>9/15/99</u>       |
| I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEES" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER OF PATENTS, BOX PATENT APPLICATION, WASHINGTON, D.C. 20231 |                      |
| <u>Mikhail Bayley</u>   |                      |
| (TYPED OR PRINTED NAME OF PERSON MAILING PAPER)   |                      |
| <u>Mikhail Bayley</u>   |                      |
| (SIGNATURE OF PERSON MAILING PAPER OR FEE)  |                      |

APPLICATION

For

UNITED STATES LETTERS PATENT

on

CACNA1G POLYNUCLEOTIDE POLYPEPTIDE AND METHODS OF USE  
THEREFOR

by

Jean-Pierre Issa

Sheets of Drawings: Eleven

Docket No.: JHU1590

Attorneys

Gray Cary Ware & Freidenrich LLP  
4365 Executive Drive, Suite 1600  
San Diego, California 92121-2189

**CACNA1G POLYNUCLEOTIDE , POLYPEPTIDE and METHODS OF USE  
THEREFOR**

**STATEMENT AS TO FEDERALLY SPONSORED RESEARCH**

5

This invention was made with Government support under Grant No. CA43318 and CA54396, awarded by the National Cancer Institute and Grant No. CA43318, a Colon Cancer Spore Grant. The government may have certain rights in the invention.

10

**FIELD OF THE INVENTION**

The present invention relates generally to the regulation of gene expression and more specifically to a method of determining the DNA methylation status of CpG sites in a given locus and correlating the methylation status with the presence of a cell proliferative disorder.

15

**BACKGROUND OF THE INVENTION**

DNA methylases transfer methyl groups from the universal methyl donor S-adenosyl methionine to specific sites on the DNA. Several biological functions have been attributed to the methylated bases in DNA. The most established biological function for methylated DNA is the protection of DNA from digestion by cognate restriction enzymes. The restriction modification phenomenon has, so far, been observed only in bacteria. Mammalian cells, however, possess a different methylase that exclusively methylates cytosine residues that are 5' neighbors of guanine (CpG). This modification of cytosine residues has important regulatory effects on gene expression, especially when involving CpG rich areas, known as CpG islands, located in the promoter regions of many genes.

20

25

- Methylation has been shown by several lines of evidence to play a role in gene activity, cell differentiation, tumorigenesis, X-chromosome inactivation, genomic imprinting and other major biological processes (Razin, A., H., and Riggs, R.D. eds. in DNA Methylation Biochemistry and Biological Significance, Springer-Verlag, New York, 1984).
- 5 In eukaryotic cells, methylation of cytosine residues that are immediately 5' to a guanosine, occurs predominantly in CG poor regions (Bird, A., *Nature*, **321**:209, 1986). In contrast, CpG islands remain unmethylated in normal cells, except during X-chromosome inactivation (Migeon, et al., *supra*) and parental specific imprinting (Li, et al., *Nature*, **366**:362, 1993) where methylation of 5' regulatory regions can lead to
- 10 transcriptional repression. De novo methylation of the Rb gene has been demonstrated in a small fraction of retinoblastomas (Sakai, et al., *Am. J. Hum. Genet.*, **48**:880, 1991), and recently, a more detailed analysis of the VHL gene showed aberrant methylation in a subset of sporadic renal cell carcinomas (Herman, et al., *Proc. Natl. Acad. Sci., U.S.A.*, **91**:9700, 1994). Expression of a tumor suppressor gene can also be abolished by de novo
- 15 DNA methylation of a normally unmethylated CpG island (Issa, et al., *Nature Genet.*, **7**:536, 1994; Herman, et al., *supra*; Merlo, et al., *Nature Med.*, **1**:686, 1995; Herman, et al., *Cancer Res.*, **56**:722, 1996; Graff, et al., *Cancer Res.*, **55**:5195, 1995; Herman, et al., *Cancer Res.*, **55**:4525, 1995).
- 20 Human cancer cells typically contain somatically altered nucleic acid, characterized by mutation, amplification, or deletion of critical genes. In addition, the nucleic acid from human cancer cells often displays somatic changes in DNA methylation (E.R. Fearon, et al., *Cell*, **61**:759, 1990; P.A. Jones, et al., *Cancer Res.*, **46**:461, 1986; R. Holliday, *Science*, **238**:163, 1987; A. De Bustros, et al., *Proc. Natl. Acad. Sci., USA*, **85**:5693, 1988); P.A. Jones, et al., *Adv. Cancer Res.*, **54**:1, 1990; S.B. Baylin, et al.,
- 25 *Cancer Cells*, **3**:383, 1991; M. Makos, et al., *Proc. Natl. Acad. Sci., USA*, **89**:1929, 1992; N. Ohtani-Fujita, et al., *Onco-gene*, **8**:1063, 1993). However, the precise role of abnormal DNA methylation in human tumorigenesis has not been established.

Aberrant methylation of normally unmethylated CpG islands has been described as a frequent event in immortalized and transformed cells, and has been associated with transcriptional inactivation of defined tumor suppressor genes in human cancers. In the development of colorectal cancers (CRC), a series of tumor suppressor genes (TSG) such as APC, p53, DCC and DPC4 are inactivated by mutations and chromosomal deletions (reviewed in Kinzler and Vogelstein 1996). Some of these alterations result from a chromosomal instability phenotype described in a subset of CRC (Lengauer et al., 1997a). Recently, an additional pathway has been shown to be involved in a familial form of CRC, hereditary non-polyposis colorectal cancer. The cancers from these patients show a characteristic mutator phenotype which causes microsatellite instability (MI), and mutations at other gene loci such as TGF-beta-RII (Markowitz et al., 1995) and BAX (Rampino et al., 1997). This phenotype usually results from mutations in the mismatch repair (MMR) genes hMSH2 and hMLH1 (reviewed by Peltomaki, and de la Chapelle, 1997). A subset of sporadic CRC also show MI, but mutations in MMR genes appear to be less frequent in these tumors (Liu et al., 1995; Moslein et al., 1996).

Another molecular defect described in CRC is CpG island (CGI) methylation. CGIs are short sequences rich in the CpG dinucleotide and can be found in the 5' region of about half of all human genes. Methylation of cytosine within 5' CGIs is associated with loss of gene expression and has been seen in physiological conditions such as X chromosome inactivation and genomic imprinting (reviewed in Latham, 1996). Aberrant methylation of CGIs has been detected in genetic diseases such as the fragile-X syndrome, in aging cells and in neoplasia. About half of the tumor suppressor genes which have been shown to be mutated in the germline of patients with familial cancer syndromes have also been shown to be aberrantly methylated in some proportion of sporadic cancers, including Rb, VHL, p16, hMLH1, and BRCA1 (reviewed in Baylin, S.B., Herman, J.G., Graff, J.R., Vertino, P.M. and Issa, J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia, *Adv. Cancer Res.* 22:141-196 1998).

TSG methylation in cancer is usually associated with (1) lack of gene transcription and (2) absence of coding region mutation. Thus it has been proposed that CGI methylation serves as an alternative mechanism of gene inactivation in cancer.

- 5           The causes and global patterns of CGI methylation in human cancers remain poorly defined. Aging could play a factor in this process because methylation of several CGIs could be detected in an age-related manner in normal colon mucosa as well as in CRC (Issa, J.P., Vertino. P.M., Boehm, C.D., Newsham, I.F. and Baylin, S.B. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nat Genet.* 7:536-540, 1994). In addition, aberrant methylation of CGIs has been associated with the MI phenotype in CRC as well as specific carcinogen exposures (Issa et al., 1996) supra. However, an understanding of aberrant methylation in CRC has been somewhat limited by the small number of CGIs analyzed to date. In fact, previous studies have suggested that large numbers of CGIs are methylated in immortalized cell lines
- 10           (Antequera, F., Boyes, J. and Bird, A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. *Cell* 62:503-514, 1990), and it is not well understood whether this global aberrant methylation is caused by the cell culture conditions or whether they are an integral part of the pathogenesis of cancer.
- 15           Most of the methods developed to date for detection of methylated cytosine depend upon cleavage of the phosphodiester bond alongside cytosine residues, using either methylation-sensitive restriction enzymes or reactive chemicals such as hydrazine which differentiate between cytosine and its 5-methyl derivative. Genomic sequencing protocols which identify a 5-MeC residue in genomic DNA as a site that is not cleaved by
- 20           any of the Maxam Gilbert sequencing reactions have also been used, but still suffer disadvantages such as the requirement for large amount of genomic DNA and the difficulty in detecting a gap in a sequencing ladder which may contain bands of varying intensity.
- 25

Mapping of methylated regions in DNA has relied primarily on Southern hybridization approaches, based on the inability of methylation-sensitive restriction enzymes to cleave sequences which contain one or more methylated CpG sites. This method provides an assessment of the overall methylation status of CpG islands, including some quantitative analysis, but is relatively insensitive and requires large amounts of high molecular weight DNA.

Another method utilizes bisulfite treatment of DNA to convert all unmethylated cytosines to uracil. The altered DNA is amplified and sequenced to show the methylation status of all CpG sites. However, this method is technically difficult, labor intensive and without cloning amplified products, it is less sensitive than Southern analysis, requiring approximately 10% of the alleles to be methylated for detection.

Identification of the earliest genetic changes in tumorigenesis is a major focus in molecular cancer research. Diagnostic approaches based on identification of these changes are likely to allow implementation of early detection strategies and novel therapeutic approaches targeting these early changes might lead to more effective cancer treatment.

## **SUMMARY OF THE INVENTION**

The present invention is based on the finding that several genes are newly identified as being differentially methylated in cancer. This seminal discovery is useful for cancer screening, risk-assessment, prognosis, minimal-residual disease identification, staging and identification of therapeutic targets. The identification of new genes that are methylated in cancer, aging or diseases associated with aging increases the likelihood of finding genes methylated in a particular cancer; increases the sensitivity and specificity of





methylation detection; allows methylation profiling using multiple genes; and allows identification of new targets for therapeutic intervention. The invention also provides a newly identified gene that is a target for hypermethylation in human tumors. This new gene, as well as genes newly identified as hypermethylated in cancer and aging or aging diseases provides markers which can be used diagnostically, prognostically and therapeutically over the course of such disorders.

In a first embodiment, the invention provides a nucleic acid molecule comprising a coding region for a T-type calcium channel, CACNA1G, and regulatory sequences associated therewith. The discovery of CpG islands, and in particular, methylated CpG islands in the region approximately 300-800 base pairs upstream from the CACNA1G translation initiation start site, led to a method of the present invention for correlating methylated CpG islands with various cancers. In one aspect of this embodiment, the nucleic acid molecule encoding CACNA1G and the associated regulatory sequences and CpG-rich regions include the nucleic acid sequence set forth in SEQ ID NO:51 (Figure 3A). Also provided is a polypeptide having an amino acid sequence as set forth in SEQ ID NO:52 and Figure 3B. The methylation state of CpG islands in CACNA1G, associated regulatory regions, and other genes is indicative of the presence of a cellular proliferative disorder in a subject from which the CpG-containing nucleic acid is isolated.

In another embodiment, there are provided methods for detecting a cellular proliferative disorder in a subject. The subject may have or be at risk of having a cellular proliferative disorder. The method of the invention is useful for diagnostic as well as prognostic analyses. One method for detecting a cellular proliferative disorder in a subject includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene; and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being

different when compared to the same regions of the gene or associated regulatory region in a subject not having the cellular proliferative, thereby detecting a cellular proliferative disorder in the subject. The method includes multiplexing by utilizing a combination of primers for more than one loci, thereby providing a methylation "profile" for more than one gene or regulatory region.

For the first time, the invention provides methylated forms of the following genes and/or their associated regulatory sequences: APOB, CACNA1G, CDX2, EGFR, FBN1, GPR37, HSPA6, IQGAP2, KL, PAR2, PITX2, PTCH, SDC1, and SDC4 (see Table 5). In addition, the invention provides the CpG-rich regions from these genes that are hypermethylated (see Figures 4A-4F (SEQ ID NO:105-119)).

Invention methods include determining, in a nucleic acid-containing specimen taken from a subject, the methylation state of a gene or regulatory sequences associated therewith, wherein the expression or non-expression of the gene is associated with the presence of the cellular proliferative disorder, and identifying as having a cellular proliferative disorder a subject that has aberrant methylation of regions of the gene or associated regulatory sequences when compared to the same regions of the gene in a subject not having the cellular proliferative disorder. In one aspect of this embodiment, the methylated regions of the gene and associated regulatory sequences are contained within CpG islands (i.e., CpG rich regions). In particular, the aberrant methylation typically includes hypermethylation as compared with the same regions of the gene or regulatory sequences in a subject not having the cellular proliferative disorder.

Determining the methylation state of the gene includes contacting the nucleic acid-containing specimen with an agent that modifies unmethylated cytosine, amplifying a CpG-containing nucleic acid in the specimen by means of CpG-specific oligonucleotide primers, wherein the oligonucleotide primers distinguish between modified methylated

and nonmethylated nucleic acid, and detecting the methylated nucleic acid based on the presence or absence of amplification products produced in said amplifying step. The method includes optionally contacting the amplification products with a methylation sensitive restriction endonuclease. Other methods for determining methylation status of a gene and/or regulatory sequences are well known in the art and are described more fully herein.

In another embodiment, the present invention provides a method of treating a cell proliferative disorder associated with CACNA1G or other methylated genes described herein, comprising administering to a subject with the disorder, a therapeutically effective amount of reagent which modulates CACNA1G or other methylated genes' expression. For example, since CACNA1G -associated disorders typically involve hypermethylation of CACNA1G polynucleotide sequence, a polynucleotide sequence which contains a non-methylatable nucleotide analog is utilized for treatment of a subject. Further, the invention provides a method of gene therapy comprising introducing into cells of a host subject, an expression vector comprising a nucleotide sequence encoding CACNA1G or other methylated genes described herein, in operable linkage with a promoter.

In another embodiment of the present invention there is provided a kit useful for the detection of a cellular proliferative disorder in a subject having or at risk for having a cellular proliferative disorder. Invention kits include a carrier means compartmentalized to receive a sample, one or more containers comprising a first container containing a reagent which modifies unmethylated cytosine and a second container containing primers for amplification of a CpG-containing nucleic acid, wherein the primers distinguish between modified methylated and nonmethylated nucleic acid, and optionally, a third container containing a methylation sensitive restriction endonuclease.

### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1A shows the relative positions of MINT31 and CACNA1G and associated CpG regions.

5        Figure 1B provides a magnified depiction of MINT31, CACNA1G and CpG rich regions 1-8.

Figure 2 depicts the correlation of methylation and the expression of CACNA1G.

Figures 3A and 3B show the nucleic acid sequence and deduced amino acid sequence of CACNA1G (SEQ ID NO:51 and 52, respectively).

10       Figures 4A-4F show the CpG-rich regions of the genes depicted in Table 5 (SEQ ID NO:105-119).

Figure 5 is the nucleotide sequence of MINT31. (SEQ ID NO:120).

### **DETAILED DESCRIPTION OF THE INVENTION**

15

It has been determined that an aberrant methylation state of nucleic acids in certain genes, particularly regulatory sequences, is diagnostic for the presence or potential development of a cellular proliferative disorder in subjects bearing the aberrantly methylated nucleic acids. More particularly, the hypermethylation of certain nucleotides localized in CpG islands has been shown to affect the expression of genes associated with the CpG islands; typically such hypermethylated genes have reduced or abolished expression, primarily due to down-regulated transcription. Using a recently developed PCR-based technique called methylated CpG island amplification (MCA), several nucleic acid molecules aberrantly methylated in a colon cancer cell line were identified. One

20       DNA fragment, termed MINT31, mapped to human chromosome 17q21 where frequent loss of heterozygosity (LOH) has been detected in various human tumors. By characterizing the genomic sequence around this area, a gene encoding a T-type calcium channel, CACNA1G, was identified as a target for hypermethylation in human tumors. Using RT-PCR, expression of CACNA1G was detected in normal colon and bone

25

marrow, but expression was absent in 5 tumor cell lines where methylation was found. After treatment with the methylation inhibitor 5-deoxy-azacytidine, the expression of CACNA1G was restored in all 5 cell lines. Detailed methylation mapping of the 5'CpG island by bisulfite-PCR revealed that methylation of a region 300 to 800 base pairs upstream of the translation initiation site closely correlated with the inactivation of CACNA1G. Aberrant methylation of CACNA1G was also examined in various human primary tumors, and was detected in 17 of 49 (35%) colorectal cancers, 4 of 16 (25%) gastric cancers, and 3 of 23 (13%) acute myelogenous leukemia cases. While not wanting to be bound by a particular theory, it is believed that inactivation of CACNA1G may play a role in cancer development by modulating calcium signaling, which potentially affects cell proliferation and apoptosis.

Thus, in one embodiment of the present invention, there are provided nucleic acids comprising the coding region for a T-type calcium channel and regulatory sequences associated therewith. Specifically, the T-type calcium channel and associated regulatory sequences comprise CACNA1G. In a more preferred embodiment, the CACNA1G is the human form of the gene. An exemplary CACNA1G gene and associated regulatory sequences is set forth in SEQ ID NO:51.

The invention provides methylated and unmethylated nucleic acid encoding CACNA1G (SEQ ID NO:51). Polynucleotides include DNA, cDNA and RNA sequences which encode CACNA1G polypeptide (SEQ ID NO:52). It is understood that naturally occurring, synthetic, and intentionally manipulated polynucleotides are included. For example, CACNA1G nucleic acid may be subject to site-directed mutagenesis, or the like. The nucleic acid sequences for CACNA1G also include antisense sequences, and sequences encoding dominant negative forms of CACNA1G, as well as sequences encoding functional fragments thereof. It is understood that naturally occurring, synthetic, and intentionally manipulated polynucleotides are included.

Methylated nucleic acid sequences are also provided. For the first time, the present invention provides methylated chemical structures for the following genes: APOB, CACNA1G, CDX2, EGFR, FBN1, GPR37, HSPA6, IQGAP2, KL, PAR2, 5 PITX2, PTCH, SDC1, and SDC4. One of skill in the art can now readily locate the CpG-rich sequences associated with these genes and identify such methylated forms of the genes/regulatory sequences by methods described herein (The gene sequences can be identified in a gene database found at <http://www.ncbi.nlm.nih.gov/UniGene/index.html>). The invention provides CpG-rich regions from the above genes as set forth in SEQ ID 10 Nos:105-119. Thus, in yet another embodiment, the invention provides an isolated 10 nucleic acid molecule having at least one methylated Cytosine of a CpG dinucleotide in a CpG-rich region and encoding a gene selected from APOB, CACNA1G, CDX2, EGFR, FBN1, GPR37, HSPA6, IQGAP2, KL, PAR2, PITX2, PTCH, SDC1, and SDC4. The methylated C residue of a CpG dinucleotide is located within a CpG-rich region selected 15 from SEQ ID NO:105-118 and SEQ ID NO:119.

The polynucleotides of the invention include "degenerate variants" which are sequences that encode the same polypeptide yet vary in sequence as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one 20 codon. Therefore, all degenerate nucleotide sequences are included in the invention as long as the amino acid sequence of a polypeptide encoded by the nucleotide sequence of SEQ ID NO:51 is functionally unchanged.

The term "polynucleotide" or "nucleic acid sequence" refers to a polymeric form 25 of nucleotides at least 10 bases in length. An "isolated polynucleotide" is a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, an isolated

polynucleotide may include a coding region with its associated regulatory sequences.

The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA)

- 5 independent of other sequences. The nucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. Specifically, methylated forms of nucleotides in a polynucleotide sequence, such as regions 1-8 of CACNA1G as described herein, are also included. The term includes single and double forms of DNA.

- 10 As will be understood by those of skill in the art, when the sequence is RNA, the deoxynucleotides A, G, C, and T of SEQ ID NO:51, are replaced by ribonucleotides A, G, C, and U, respectively. Also included in the invention are fragments of the above-described nucleic acid sequences that are at least 15 bases in length, which is sufficient to permit the fragment to selectively hybridize to DNA that encodes SEQ ID NO:52. The term “selectively hybridize” refers to hybridization under moderately or highly stringent conditions (See, Maniatis, as cited herein) which excludes non-related nucleotide sequences.

- 20 The CACNA1G nucleic acid sequence includes the disclosed sequence and sequences that encode conservative variations of the polypeptides encoded by CACNA1G polynucleotide provided herein. The term “conservative variation” as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like. The term “conservative variation” also includes the use of a substituted amino acid in place of an unsubstituted
- 25

parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

CACNA1G nucleic acid sequences can be expressed in vitro by DNA transfer into  
5 a suitable host cell. "Host cells" are cells in which a vector can be propagated and its  
DNA expressed. The cell may be prokaryotic or eukaryotic. The term also includes any  
progeny of the subject host cell. It is understood that all progeny may not be identical to  
the parental cell since there may be mutations that occur during replication. However,  
such progeny are included when the term "host cells" is used. Methods of stable transfer,  
10 meaning that the foreign DNA is continuous-ly maintained in the host, are known in the  
art.

In one aspect, the CACNA1G nucleic acid sequences may be inserted into an  
expression vector. The term "expression vector" refers to a plasmid, virus or other  
15 vehicle known in the art that has been manipulated by insertion or incorporation of the  
sequence of interest genetic sequences. Polynucleotide sequence which encode sequence  
of interest can be operatively linked to expression control sequences. "Operatively  
linked" refers to a juxtaposition wherein the components so described are in a  
relationship permitting them to function in their intended manner. An expression control  
20 sequence operatively linked to a coding sequence is ligated such that expression of the  
coding sequence is achieved under conditions compatible with the regulatory or  
expression control sequences. As used herein, the terms "regulatory sequences" and  
"expression control sequences" refers to nucleic acid sequences that regulate the  
expression of a nucleic acid sequence to which it is operatively linked. Expression  
25 control sequences are operatively linked to a nucleic acid sequence when the expression  
control sequences control and regulate the transcription and, as appropriate, translation of  
the nucleic acid sequence. Thus expression control sequences can include appropriate  
promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of a



protein-encoding gene, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons. The terms "regulatory sequences" and "expression control sequences" are intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. An example of an expression control sequence includes a promoter.

A "promoter" is a minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the gene. Both constitutive and inducible promoters, are included in the invention (see, e.g., Bitter et al., *Methods in Enzymology* 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.

In the present invention, the CACNA1G polynucleotide sequence may be inserted into an expression vector which contains a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the

present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg et al., Gene 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem. 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells. The DNA segment  
 5 can be present in the vector operably linked to regulatory elements, for example, a promoter (e.g., T7, metallothionein I, or polyhedron promoters).

CACNA1G polynucleotide sequences can be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect and mammalian organisms.  
 10 Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorporate DNA sequences of the invention.

15 “Transformation” means a genetic change induced in a cell following incorporation of new DNA (i.e., DNA exogenous to the cell). Where the cell is a mammalian cell, the genetic change is generally achieved by introduction of the DNA into the genome of the cell (i.e., stable).

20 Thus, a “transformed cell” is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding sequence of interest. Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as E. coli, competent cells which are capable of DNA uptake can  
 25 be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl<sub>2</sub> method using procedures well known in the art. Alternatively, MgCl<sub>2</sub> or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired.

When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransformed with DNA sequences encoding the sequence of interest, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein (see for example, Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).

Methods which are well known to those skilled in the art can be used to construct expression vectors containing the CACNA1G coding sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo recombination/genetic techniques. See, for example, the techniques described in Maniatis, et al., 1989 Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.

A variety of host-expression vector systems may be utilized to express the CACNA1G coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the CACNA1G coding sequence; yeast transformed with recombinant yeast expression vectors containing the CACNA1G coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the CACNA1G coding sequence; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the CACNA1G coding sequence; or animal cell systems infected

with recombinant virus expression vectors (e.g., retroviruses, adenovirus, vaccinia virus) containing the CACNA1G coding sequence, or transformed animal cell systems engineered for stable expression. Since CACNA1G has not been confirmed to contain carbohydrates, both bacterial expression systems as well as those that provide for translational and post-translational modifications may be used; e.g., mammalian, insect, yeast or plant expression systems.

Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see e.g., Bitter, et al., *Methods in Enzymology* 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage .gamma., plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the inserted CACNA1G coding sequence. In addition, the endogenous CACNA1G promoter may also be used to provide transcription machinery of CACNA1G .

In bacterial systems a number of expression vectors may be advantageously selected depending upon the use intended for the expressed. For example, when large quantities of CACNA1G are to be produced, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Those which are engineered to contain a cleavage site to aid in recovering are preferred. Such vectors include but are not limited to the E. coli expression vector pUR278 (Ruther, et al., *EMBO J.* 2:1791, 1983), in which the CACNA1G coding sequence may be ligated into the

vector in frame with the lac Z coding region so that a hybrid -lac Z protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.*, 13:3101-3109, 1985; Van Heeke & Schuster, *J. Biol. Chem.* 264:5503-5509, 1989); glutathione-S-transferase (GST) and the like.

5

In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review see, *Current Protocols in Molecular Biology*, Vol. 2, 1988, Ed. Ausubel, et al., Green Publish. Assoc. & Wiley Interscience, Ch. 13; Grant, et al., 1987, *Expression and Secretion Vectors for Yeast*, in *Methods in Enzymology*, Eds. Wu & Grossman, 31987, Acad. Press, N.Y., Vol. 153, pp. 516-544; Glover, 1986, *DNA Cloning*, Vol. II, IRL Press, Wash., D.C., Ch. 3; and Bitter, 1987, *Heterologous Gene Expression in Yeast*, *Methods in Enzymology*, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684; and *The Molecular Biology of the Yeast Saccharomyces*, 1982, Eds. Strathern, et al., Cold Spring Harbor Press, Vols. I and II. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used (Cloning in Yeast, Ch. 3, R. Rothstein In: *DNA Cloning Vol.11, A Practical Approach*, Ed. DM Glover, 1986, IRL Press, Wash., D.C.). Alternatively, vectors may be used which promote integration of foreign DNA sequences into the yeast chromosome.

In cases where plant expression of the CACNA1G coding sequence may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brisson, et al., *Nature* 310:511-514, 1984), or the coat protein promoter to TMV (Takamatsu, et al., *EMBO J.* 6:307-311, 1987) may be used; alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi, et al., *EMBO J.* 3:1671-1680, 1984; Broglie, et al., *Science* 224:838-843, 1984); or heat shock promoters, e.g., soybean hsp17.5-E or hsp17.3-B (Gurley, et al., *Mol. Cell. Biol.* 6:559-565, 1986) may be used. These constructs can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection,

electroporation, etc. For reviews of such techniques see, for example, Weissbach & Weissbach, 1988, *Methods for Plant Molecular Biology*, Academic Press, N.Y., Section VIII, pp. 421-463; and Grierson & Corey, 1988, *Plant Molecular Biology*, 2d Ed., Blackie, London, Ch. 7-9.

5

An alternative expression system which could be used to express is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The CACNA1G coding sequence may be cloned into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the CACNA1G coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera* frugiperda cells in which the inserted gene is expressed. (e.g., see Smith, et al., 1983, *J. Virol.* 46:584; Smith, U.S. Pat. No. 4,215,051).

Eukaryotic systems, and preferably mammalian expression systems, allow for proper post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, phosphorylation, and advantageously, secretion of the gene product may be used as host cells for the expression of CACNA1G. Mammalian cell lines may be preferable. Such host cell lines may include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, -293, and W138.

25

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, the CACNA1G coding sequence may be ligated to an adenovirus

transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of

5 expressing the protein in infected hosts (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA, 81:3655-3659, 1984). Alternatively, the vaccinia virus 7.5K promoter may be used (e.g., see, Mackett, et al., 1982, Proc. Natl. Acad. Sci. USA 79:7415-7419; Mackett, et al., J. Virol. 49:857-864, 1984; Panicali, et al., Proc. Natl. Acad. Sci. USA 79:4927-4931, 1982). Of particular interest are vectors based on bovine papilloma virus which have the

10 ability to replicate as extrachromosomal elements (Sarver, et al., Mol. Cell. Biol. 1:486, 1981). Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable

15 marker in the plasmid, such as, for example, the neo gene. Alternatively, the retroviral genome can be modified for use as a vector capable of introducing and directing the expression of the CACNA1G gene in host cells (Cone & Mulligan, Proc. Natl. Acad. Sci. USA 81:6349-6353, 1984). High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionein IIA promoter and

20 heat shock promoters.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with the CACNA1G cDNA controlled by appropriate

25 expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be

cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al.,  
 5 Cell, 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48:2026, 1962), and adenine  
 phosphoribosyltransferase (Lowy, et al., Cell, 22: 817, 1980) genes can be employed in tk.sup.-, hgpT.sup.- or apt.sup.- cells respectively. Also, antimetabolite resistance can be  
 used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler,  
 10 et al., Natl. Acad. Sci. USA, 77:3567, 1980; O'Hare, et al., Proc. Natl. Acad. Sci. USA, 78: 1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78: 2072, 1981; neo which confers resistance to the  
 aminoglycoside G-418 (Colberre-Garapin, et al., J. Mol. Biol., 150:1, 1981); and hygromycin, which confers resistance to hygromycin (Santerre, et al., Gene, 30:147, 1984) genes.  
 15 Recently, additional selectable genes have been described, namely trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histidinol in place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. USA, 85:8047, 1988); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., 1987, In: Current  
 20 Communications in Molecular Biology, Cold Spring Harbor Laboratory, ed.).

Isolation and purification of microbial expressed polypeptide, or fragments thereof, provided by the invention, may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or  
 25 polyclonal antibodies.

In one embodiment, the invention provides substantially purified polypeptide encoded by CACNA1G polynucleotide sequences. Exemplary CACNA1G polypeptide



is set forth in SEQ ID NO:52. The term "substantially purified" as used herein refers to a polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify a polypeptide encoded by CACNA1G polynucleotide sequence using standard techniques for protein purification. The substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. The purity of the CACNA1G polypeptide can also be determined by amino-terminal amino acid sequence analysis.

Minor modifications of the CACNA1G primary amino acid sequences may result in proteins which have substantially equivalent activity as compared to the unmodified counterpart polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as the biological activity still ex-ists.

The polypeptides of the invention also include dominant negative forms of the CACNA1G polypeptide which do not have the biological activity of CACNA1G polypeptide sequence. A "dominant negative form" of CACNA1G is a polypeptide that is structurally similar to CACNA1G polypeptide but does not have wild-type CACNA1G function. For example, a dominant-negative CACNA1G polypeptide may interfere with wild-type CACNA1G function by binding to, or otherwise sequestering, regulating agents, such as upstream or downstream components, that normally interact functionally with the CACNA1G polypeptide.

#### Identification and Isolation of CACNA1G

To identify genes differentially methylated in colorectal cancer, methylated CpG island amplification was used followed by representational difference analysis (Razin and Cedar, Cell 17: 473-476, 1994, herein incorporated by reference). One of the clones

recovered (MINT31, see U.S. Patent Application Serial No. 09/309,175, incorporated by reference herein in its entirety) mapped to human chromosome 17q21 using a radiation hybrid panel. A Blast search revealed this fragment to be completely identical to part of a BAC clone (Genbank: AC004590) sequenced by high throughput genomic sequencing.

- 5 The region surrounding MINT31 fulfills the criteria of a CpG island: GC content 0.67, CpG/GpC ratio 0.78 and a total of 305 CpG sites in a 4 kb region. Using this CpG island and 10 kb of flanking sequences in a Blast analysis, several regions highly homologous to the rat T-type calcium channel gene, CACNA1G, were identified (Perez-Reyes et al., Nature 391: 896-900. 1998, herein incorporated by reference). Several ESTs were also
- 10 identified in this region. Using Genscan, 2 putative coding sequences (G1, and G2) were identified. Blastp analysis revealed that G1 has a high homology to the EH-domain-binding protein, epsin, while G2 is homologous to a C. elegans hypothetical protein (accession No. 2496828).

- 15 The MINT31 CpG island corresponds to the 3' regions of G1 and G2, based on the direction of the open reading frame and the presence of a poly A tail, and, without being bound by theory, is unlikely to influence their transcription. The EST closest to MINT31 (H13333) (SEQ ID NO:120; Figure 5) was sequenced entirely and was found not to contain a continuous open reading frame, but a poly-adenylation signal was
- 20 identified on one end, along with a poly A tail. These data suggest that H13333 corresponds to the last 2 exons of an unidentified gene. MINT31 is in the intron of this gene and is, again without being bound by theory, unlikely to influence transcription of the unidentified gene. However, based on both promoter prediction (TSSG) analysis of this region and homology to the rat CACNA1G sequence, the MINT31 CpG island is also
- 25 in the 5' region of human CACNA1G gene and is likely to play a role in its transcriptional activity.

The human CACNA1G sequence deposited in Genbank lacks the 5' region of the gene, when compared to the rat homologue. To determine the 5' region of human CACNA1G, cDNA was amplified by RT-PCR using primers based on the BAC sequence (Genbank: AC004590, herein incorporated by reference). The PCR products were cloned and sequenced, and the genomic organization of the gene was determined by comparing the newly identified sequences as well as the known sequences to the BAC that covers this region. CACNA1G is composed of 34 exons which span a 70 kb area. (See, Figure 3A and SEQ ID NO:52). Based on sequences deposited in Genbank, the gene has two possible 3' ends caused by alternate splicing. Human CACNA1G is highly homologous to rat CACNA1G with 93% identity at the protein level, and 89% identity at the nucleotide level. The 5' flanking region of human CACNA1G lacks TATA and CAAT boxes, which is similar to many housekeeping genes. A putative TFIID binding site was identified 547-556 bp upstream from the translation start site, and several other potential transcription factor binding sites such as AP1 (1 site), AP2 (2 sites) and SP1 (10 sites), were identified upstream of CACNA1G exon 1 using the promoter prediction program, TESS.

### Methylation Analysis of CACNA1G

The CACNA1G CpG island is 4 kb, and is larger than many typical CpG islands. MINT31 corresponds to the 5' edge of the island while CACNA1G is in the 3' region. It is not known whether large CpG islands such as this are coordinately regulated with regards to protection from methylation, and aberrant methylation in cancer.

To address this issue, the methylation status of the 5' region of CACNA1G was studied using bisulfite-PCR of DNA from normal tissues as well as 35 human cancer cell lines from colon, lung, prostate, breast and hematopoietic tumors. More specifically, forty-nine primary colorectal cancers, 28 colorectal adenomas, 16 primary gastric cancers and 17 acute myelogenous leukemia samples were used for methylation analyses. DNA

from eight colon cancer cell lines (Caco2, RKO, SW48, HCT116, DLD1, Lovo, SW837, HT29), 4 lung cancer cell lines (OH3, H249, H157, H209), 4 glioblastoma cell lines (Dauy, D283, U87, U373), 8 breast cancer cell lines (MB-468, MCF7, MB-231, MB-474, MB-435, MB-453, BT20, CAMA1, SKBR3), 7 hematopoietic tumor cell lines (CEM, Raji, KG1A, HL60, ML-1, MoIt3, K562), and 4 prostate cancer cell lines (DU145, DUPRO, LNCAP, TSUPRL) were also investigated. The CpG island was divided into 8 regions (SEQ ID NOs: 35-42, respectively). The methylation status of each region was examined separately. The genomic DNA was treated with sodium bisulfite and PCR amplified using primers containing no or a minimum number of CpG sites. (For a detailed description of bisulfite-PCR, see, U.S. Patent No. 5,786,146, incorporated herein by reference in its entirety). Methylated alleles were detected by digesting the PCR products using restriction enzymes which specifically cleave sites created or retained due to the presence of methylated CpGs. None of the regions was methylated in normal colon, consistent with a uniform protection against de-novo methylation.

Regions 1 and 2 were frequently methylated in cancer cell lines, and behaved in a concordant manner with respect to methylation pattern. Indeed, these 2 regions were methylated in most cancer cell types except gliomas. Moreover, most cell lines where methylation was found methylated both regions 1 and 2. In contrast, region 3, which is less CG rich than any of the other regions, had either no methylation or very low levels of methylation in most cell lines. Regions 5, 6, and 7 behaved quite differently compared to 1-3. Methylation of these regions was less frequent than regions 1-2, as 22/35 cell lines had no detectable methylation there, despite often showing methylation of region 1-2. However, when methylation of regions 5, 6, or 7 was present (in 13/35 cell lines), it affected all 3 regions in a coordinate manner, although to varying extents. Finally, regions 4 and 8 behaved differently again, being partially methylated primarily in colon and breast cell lines. Therefore, with regards to hypermethylation in cancer cells, the CpG rich region upstream of CACNA1G appears to be composed of 2 CpG islands which

behave independently. MINT31 corresponds to the upstream CpG island (island 1, regions 1 and 2), while the 5' region of CACNA1G is contained in the downstream CpG island (island 2, regions 5-7). Regions 3, 4 and 8 correspond to the edge of these CpG islands, and behave a little differently than the hearts of the CpG islands, as previously described for the E-Cad gene (Graff, et al., J. Biol. Chem. 272: 22322-22329, 1997).

Overall, the methylation patterns of CACNA1G fell into 5 distinct categories: (1) No methylation in any region (normal tissue). (2) Slight methylation of island 1 (6 cell lines, e.g., TSU-PRL). (3) Heavy methylation of island 1 but no methylation of island 2 (16 cell lines, e.g., Caco2). (4) Heavy methylation of island 1 and moderate to heavy methylation of island 2 (6 cell lines, e.g., RKO and Raji). (5) High methylation of island 1 and low to moderate methylation of island 2 (7 cell lines, e.g., MB-231).

#### Methylation Dependent Expression of CACNA1G

In a previous study, rat CACNA1G was shown to be expressed most abundantly in the brain (Perez-Reyes et al., Nature 391: 896-900. 1998). To determine the expression of CACNA1G in normal and neoplastic human cells, RT-PCR was performed using cDNA from various normal tissues and from a panel of 27 tumor cell lines. CACNA1G was expressed ubiquitously in a variety of tissues and cell lines. In normal tissues expression was relatively low but easily detectable, while most cell lines had relatively high expression of CACNA1G. However, some cell lines had negligible or totally absent levels of CACNA1G expression. The results of CACNA1G expression was correlated with the detailed methylation analysis previously described. In this analysis, a remarkable pattern emerged. Methylation of regions 1-4 and 8 had no effect on CACNA1G expression. However, there was a strong correlation between methylation of regions 5-7 and expression of the gene. In fact, all cell lines tested that lack methylation of this region strongly express the gene. All 6 cell lines with pattern 4 methylation studied had no

detectable expression. Finally, the 7 cell lines with pattern 5 methylation (examples DLD-1 and MB-453) had variable levels of expression ranging from very low to near normal. The fact that patterns 3 and 5 differ significantly with regards to expression, but are almost identical with regards to methylation of all regions except 7 indicates that this area is important in the inactivation of CACNA1G.

To confirm that methylation of the 5' CpG island of CACNA1G is associated with gene inactivation, 3 non-expressing cell lines showing pattern 4 methylation (RKO, SW48 and Raji) and 2 weakly expressing cell lines showing pattern 5 methylation (MB-231 and MB-435) were treated with 1 M of the methyl-transferase inhibitor 5-deoxy-azacitidine. After treatment, all of these cell lines re-expressed CACNA1G mRNA. Consistent with re-expression, demethylation of region 7 was observed after 5-deoxy-azacitidine treatment.

De novo cytosine methylation is thought to sometimes occur in vitro during cell propagation (Antequera et al., Cell 62: 503-514, 1990). To determine whether the methylation of CACNA1G occurs in vivo, primary human tumors were examined for methylation of the 5' region of CACNA1G. Aberrant methylation was detected in 17 out of 49 (35%) colorectal cancers, 4 out of 28 colorectal adenomas (25%), 4 out of 16 (25%) gastric cancers and 3 out of 17 (18%) acute myelogenous leukemia cases. In colorectal cancers, there was a significant correlation between methylation of CACNA1G and methylation of p16 ( $p < 0.005$ ) and hMLH1 ( $p < 0.001$ ), as well as a strong correlation with the presence of microsatellite instability, and the recently identified CpG island methylator phenotype (CIMP), indicating that CACNA1G is also a target for CIMP in colorectal cancer.

To determine whether aberrant methylation of the 5' region of CACNA1G affects the expression status of this gene in primary tumors, RT-PCR was performed using

cDNA from a series of colorectal adenomas. Six out of 8 cases which showed no methylation of region 7 expressed CACNA1G. In sharp contrast, all 5 cases that showed methylation of region 7 had no detectable expression of the gene.

5            Thus, a human T-type calcium channel gene (CACNA1G) has been identified and cloned using the MINT31 sequence as a probe. The human T-type calcium channel gene has been determined to be a target of aberrant methylation and silencing in human tumors. The data show that MINT31 (for a representative sequence of MINT1-33, see, US Patent Application Serial No. 09/309,175) hereby incorporated by reference can be  
10           used as a probe to identify genes that play a role in disorders such as cell proliferative disorders.

             Detailed analysis of the CpG island upstream of CACNA1G revealed that methylation 300 to 800 bp upstream of the gene closely correlated with transcriptional  
15           inactivation. The CACNA1G promoter is contained in a large CG rich area that is not coordinately methylated in cancer. The CpG island around MINT31 is much more frequently methylated in cancers compared to that just upstream of CACNA1G. This may simply be caused by differential susceptibility to de-novo methylation between these two regions, with methylation of MINT31 serving as a trigger, and eventually spreading to  
20           CACNA1G, as described in other genes (Graff, et al., J. Biol. Chem. 272: 22322-22329, 1997). However, it is likely that these 2 regions are controlled by different mechanisms because (1) cell lines kept in culture for countless generations do not in fact spread methylation from MINT31 to CACNA1G (e.g., Caco2), (2) region 3 that separates the 2 islands is infrequently and sparsely methylated in cancer and (3) 2 cases of primary  
25           colorectal cancer were found which are methylated at the CACNA1G promoter but not at MINT31). Therefore, methylation of MINT31 appears to be independent of methylation of CACNA1G suggesting that they are 2 distinct CpG islands regulated by different mechanisms.

Many CpG islands of silenced genes appear to be methylated uniformly and heavily throughout the island (e.g., Graff, et al., J. Biol. Chem. 272: 22322-22329, 1997). In contrast the methylation patterns of the 5' region of CACNA1G (region 5-7) was

5 heterogeneous in the cell lines which did not express this gene. Nevertheless, methylation clearly plays a role in CACNA1G repression since demethylation readily reactivates the gene.

- The mechanism of CACNA1G methylation remains to be determined.
- 10 Methylation was not detected in normal colon mucosa, placenta, normal breast epithelium and normal bone marrow, including samples from aged patients, suggesting that methylation of this region is specific for cell proliferative disorders such as cancer, and the like. However, there was a significant correlation between methylation of CACNA1G and other tumor suppressor genes such as p16 and hMLH1. Thus,
- 15 CACNA1G is likely a target for the recently described CIMP phenotype, which results in a form of epigenetic instability with simultaneous inactivation of multiple genes.

- T-type calcium channels are involved not only in electrophysiological rhythm generation but also in the control of cytosolic calcium during cell proliferation and cell
- 20 death (reviewed in Berridge, et al., Nature 395: 645-648, 1998). Expression of CACNA1G is not limited to brain and heart, indicating a likely role in other tissues in which it is expressed. It has previously been shown that Ca<sup>2+</sup> influx via T-type channels is an important factor during the initial stages of cell death such as apoptosis (Berridge, et al., Nature 395: 645-648, 1998), ischemia (Fern, J. Neurosci. 18: 7232-7243, 1998) and
- 25 complement-induced cytotoxicity (Newsholme, et al., Biochem. J. 295: 773-779, 1993.). The studies culminating in the present invention indicates that impairment of voltage gated calcium channels plays an important role in cancer development and progression through altering calcium signaling.



Due to the clear correlation between methylation of CpG islands and cellular proliferative disorders, in another embodiment of the present invention, there are provided methods for detecting a cellular proliferative disorder in a subject having or at risk for said cellular proliferative disorder. The method includes assaying, in nucleic acid-containing specimen taken from said subject, the methylation state of a gene or its associated regulatory regions, wherein the expression state of the gene or its associated regulatory regions is associated with the presence of the cellular proliferative disorder, and identifying as having a cellular proliferative disorder a subject that has aberrant methylation of regions of said gene. The method provides for detecting a cellular proliferative disorder in a subject having or at risk for said cellular proliferative disorder by identifying aberrantly methylation of regions of a gene when compared to the same regions of the gene in a subject not having said cellular proliferative disorder.

The aberrant methylation comprises hypermethylated CpG rich regions (i.e., islands). In one aspect of the present invention, the CpG rich regions are associated with the CACNA1G gene, and affect the expression thereof in a methylation state-dependent manner. A "cell proliferative disorder" or "cellular proliferative disorder" is any disorder in which the proliferative capabilities of the affected cells is different from the normal proliferative capabilities of unaffected cells. An example of a cell proliferative disorder is neoplasia. Malignant cells (i.e., cancer) develop as a result of a multistep process. Specific, non-limiting examples of cell proliferative disorders associated with increased methylation of CpG-islands are low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, lung cancer, renal cancer, leukemia, breast cancer, prostate cancer, endometrial cancer and neuroblastoma.

A cell proliferative disorder as described herein may be a neoplasm. Such neoplasms are either benign or malignant. The term "neoplasm" refers to a new,

abnormal growth of cells or a growth of abnormal cells that reproduce faster than normal. A neoplasm creates an unstructured mass (a tumor) which can be either benign or malignant. For example, the neoplasm may be a head, neck, lung, esophageal, stomach, prostate, small bowel, colon, bladder, kidney, or cervical neoplasm. The term "benign" refers to a tumor that is noncancerous, e.g. its cells do not proliferate or invade surrounding tissues. The term "malignant" refers to a tumor that is metastatic or no longer under normal cellular growth control.

A cell proliferative disorder may be an age-associated disorder. Examples of age-associated disorders which are cell proliferative disorders include colon cancer, lung cancer, breast cancer, prostate cancer, leukemia and melanoma, amongst others.

A "nucleic acid containing specimen" includes any type of material containing a nucleic acid to be subject to invention methods. The nucleic acid may be contained in a biological sample. Such samples include but are not limited to any bodily fluid, such as a serum, urine, saliva, blood, cerebrospinal fluid, pleural fluid, ascites fluid, sputum, stool, or a biopsy sample.

Samples or specimens include any CpG-rich DNA sequence, whatever the origin, as long as the sequence is detectably present in a sample. While routine diagnostic tests may not be able to identify cancer cells in these samples, the method of the present invention identifies neoplastic cells derived from the primary tumor or from a metastases. The method includes non-invasive sampling (e.g., bodily fluid) as well as invasive sampling (e.g., biopsy). The sample of DNA of the subject may be serum, plasma, lymphocytes, urine, sputum, bile, stool, cervical tissue, saliva, tears, cerebral spinal fluid, regional lymph node, histopathologic margins, and any bodily fluid that drains a body cavity or organ. Therefore, the method provides for the non-invasive detection of various tumor types including head and neck cancer, lung cancer, esophageal cancer, stomach cancer, small bowel cancer, colon cancer, bladder cancer, kidney cancers, cervical cancer

and any other organ type that has a draining fluid accessible to analysis. For example, neoplasia of regional lymph nodes associated with a primary mammary tumor can be detected using the method of the invention. Regional lymph nodes for head and neck carcinomas include cervical lymph nodes, prelaryngeal lymph nodes, pulmonary juxta-esophageal lymph nodes and submandibular lymph nodes. Regional lymph nodes for mammary tissue carcinomas include the axillary and intercostal nodes. Samples also include urine DNA for bladder cancer or plasma or saliva DNA for head and neck cancer patients.

Any nucleic acid sample, in purified or nonpurified form, can be utilized as the starting nucleic acid or acids in accordance with the present invention, provided it contains, or is suspected of containing, a nucleic acid sequence containing a target locus (e.g., CpG-containing nucleic acid). In general, the CpG-containing nucleic acid is DNA. However, invention methods may employ, for example, samples that contain DNA, or DNA and RNA, including messenger RNA, wherein DNA or RNA may be single stranded or double stranded, or a DNA-RNA hybrid may be included in the sample. A mixture of nucleic acids may also be employed. The specific nucleic acid sequence to be detected may be a fraction of a larger molecule or can be present initially as a discrete molecule, so that the specific sequence constitutes the entire nucleic acid. It is not necessary that the sequence to be studied be present initially in a pure form; the nucleic acid may be a minor fraction of a complex mixture, such as contained in whole human DNA. The nucleic acid-containing sample used for detection of methylated CpG may be from any source including, but not limited to, brain, colon, urogenital, lung, renal, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, prostate and uterine tissue, and may be extracted by a variety of techniques such as that described by Maniatis, et al. (Molecular Cloning: a Laboratory Manual, Cold Spring Harbor, NY, pp 280, 281, 1982).

The nucleic acid of interest can be any nucleic acid where it is desirable to detect the presence of a differentially methylated CpG island. The CpG island comprises a CpG island located in a gene or regulatory region for a gene. A "CpG island" is a CpG rich region of a nucleic acid sequence. The nucleic acid sequence may include, for example, APOB, CACNA1G, CDX2, EGFR, FBN1, GPR37, HSPA6, IQGAP2, KL, PAR2, PITX2, PTCH, SDC1, or SDC4 (see for example Figures 4A-4F). Alternatively the nucleic acid of interest can be, for example, a MINT31 nucleic acid sequence (SEQ ID NO:120). However, any gene or nucleic acid sequence of interest containing a CpG sequence can provide diagnostic information (i.e., via its methylation state) using invention methods.

Moreover, these markers can also be multiplexed in a single amplification reaction to generate a low cost, reliable cancer screening test for many cancers simultaneously. A combination of DNA markers for CpG-rich regions of nucleic acid may be amplified in a single amplification reaction. The markers are multiplexed in a single amplification reaction, for example, by combining primers for more than one locus. For example, DNA from a urine sample can be amplified with three different randomly labeled primer sets, such as those used for the amplification of the CACNA1G, EGFR and PTCH loci, in the same amplification reaction. The reaction products are separated on a denaturing polyacrylamide gel, for example, and then exposed to film for visualization and analysis. By analyzing a panel of markers, there is a greater probability of producing a more useful methylation profile for a subject.

If the sample is impure (e.g., plasma, serum, stool, ejaculate, sputum, saliva, cerebrospinal fluid, or blood or a sample embedded in paraffin), it may be treated before amplification with a reagent effective for lysing the cells contained in the fluids, tissues, or animal cell membranes of the sample, and for exposing the nucleic acid(s) contained therein. Methods for purifying or partially purifying nucleic acid from a sample are well

known in the art (e.g., Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, 1989, herein incorporated by reference).

5 In order to detect a differential methylation state for a gene or CpG-containing region of interest, invention methods include any means known in the art for detecting such differential methylation. For example, detecting the differential methylation may include contacting the nucleic acid-containing specimen with an agent that modifies unmethylated cytosine, amplifying a CpG-containing nucleic acid in the specimen by means of CpG-specific oligonucleotide primers, wherein the oligonucleotide primers  
10 distinguish between modified methylated and nonmethylated nucleic acid, and detecting the methylated nucleic acid based on the presence or absence of amplification products produced in said amplifying step. This embodiment includes the PCR-based methods described in U.S. Patent No. 5,786,146, incorporated herein in its entirety.

15 For the first time, the methylation state of a number of genes has been correlated with cell proliferative disorders. Examples of such genes, primers useful for identifying their methylation state, and general PCR conditions are set out in Table 1.

TABLE 1 Bisulfite-PCR Primers

|    | Genes   | 5'-primer                                   | 3'-primer                    | Annealing Temperature (oC) |
|----|---------|---|------------------------------|----------------------------|
|    | APOB    | 5'-gttttttagttagttgggtttttt-3'<br>TaqI      | 5'-RccaacaacRccaacaac-3'     | 57                         |
| 5  | CACNA1G | See Table 2                                 |                              |                            |
|    | R6      | 5'-ttgttgggttgggtagattt-3'<br>HinfI         | 5'-acraaaaaaataatctt-3'      | 47TD                       |
|    | R7      | 5'-ggggggttttttgggattt-3'<br>EcoRI          | 5'-ttccctacccccctaaacttcc-3' | 49TD                       |
| 10 | CDX2    | 5'-gtaggttagaggaggatgtt-3'<br>TaqI          | 5'-aaaacaacccaccatactacct-3' | 60                         |
|    | EGFR    | 5'-tttgattYgttagtattgat-3'<br>HinfI, TaqI   | 5'-ccctacccttcttcttcc-3'     | 52                         |
|    | FBN1    | 5'-ttttttattgYgtaattttg-3'<br>TaqI          | 5'-tttcccccactcttcaataa-3'   | 54                         |
| 15 | GPR37   | 5'-ggttaggtgggtaagattt-3'<br>HinfI          | 5'-aacRtttaatccaattacaacc-3' | 56                         |
|    | HSPA6   | 5'-tttttagtagttttagtagagg-3'<br>TaqI        | 5'-tttcatccttttacacctccc-3'  | 60                         |
| 20 | IQGAP2  | 5'-ttatttttatttagtgttag-3'<br>TaqI          | 5'-ctcttcRtataacatctac-3'    | 52                         |
|    | KL      | 5'-gtagatgttgyttagtggtt-3'<br>TaqI          | 5'-aaataccctaaaaaaccc-3'     | 60                         |
|    | PAR2    | 5'-YgggttttttGaaatttaattc-3'<br>HinfI, TaqI | 5'-aactccRcatcctcctaaa-3'    | 45                         |
| 25 | PITX2   | 5'-taagtgttgyttaggtttttt-3'<br>TaqI         | 5'-ccaaactccactacacaataac-3' | 60                         |
|    | PTCHA   | 5'-gttggtttgtaatyggagt-3'<br>TaqI           | 5'-ttaccaaccraaacattatt-3'   | 60                         |
| 30 | PTCHB   | 5'-aatgtgtgggaatttagggga-3'<br>TaqI         | 5'-taaaacaaccaactacacttac-3' | 60                         |
|    | SDC1    | 5'-agagggaattgygtagtagagag-3'<br>TaqI       | 5'-cacaaccaaaccacaaac-3'     | 60                         |
| 35 | SDC4    | 5'-gggggattgtttgtagtaggg-3'<br>HinfI        | 5'-cccgaattcccccaataaa-3'    | 56                         |

Note: Y = C or T, R = G or A; row 1-SEQ ID NO:1 and 2; row 2-SEQ ID NO:3 and 4 and so forth through to SEQ ID NO:32, respectively. The gene sequences can be found in a gene database at <http://www.ncbi.nlm.nih.gov/UniGene/index.html>.

In one embodiment, the oligonucleotide primers are specifically targeted to CACNA1G and its associated CpG islands as described herein. Examples of oligonucleotides suited for determining the methylation state of the 8 regions of the two CpG islands of MINT31/CACNA1G, as well as PCR conditions and useful methylation sensitive restriction endonucleases are set out in Table 2.

TABLE 2 Primers Useful For Bisulfite/PCR Analysis of CACNA1G

| Region | Primer set, forward /reverse   | Annealing temperature (cycles) | Restriction enzyme |
|--------|--|--------------------------------|--------------------|
| 5      | Region 1 5'-GAYGGYGTAGTAGTTATTTGTT-3'  | 58 (3), 56 (4),                | BstUI              |
|        | F165 5'-CATCACCACCCCTCATTAC-3'   | 54 (5), 52 (26)                | MaeII              |
|        | Region 2 5'-TTYGGGTATTTATAGTTTTTTGGAG-3'   | 60 (3), 58 (4),                | TaqI               |
|        | GM2 5'-AATCTACRCCTTCACTCACTC-3'  | 56 (5), 54 (26)                | BstUI              |
| 10     | Region 3 5'-TTTAGGAGYGTAAATGTGAGGTT-3'   | 55 (3), 53 (4),                | HinfI              |
|        | GM3 5'-CTAAAAAAACCAATCTTAAAAAAC-3'   | 51(5), 49(26)                  | MaeII              |
|        | Region 4 5'-TGGATAAAGGATGTTGGGGTTG-3'  | 55 (5), 53 (5),                | MaeII              |
|        | GM5 5'-CCCTCCCTTACCCCTAAATCC-3'  | 51(5), 49(26)                  | TaqI               |
|        | Region 5 5'-AATYGGATTTTGTGTTGTTT-3'  | 60 (3), 58 (4),                | BstUI              |
| 15     | GM1 5'-CACACCACAATAATCCCTCACT-3'   | 56 (5), 54 (26)                | TaqI               |
|        | Region 6 5'-TTGTGGYGTGGYGATAGTT-3'   | 53 (3), 51 (4),                | HinfI              |
|        | GM6 5'-ACRAAAAAAAAAAAAAAAAAATCTCTT-3'  | 49 (5), 47 (26)                |                    |
|        | Region 7 5'-GGGGGYGTTTTTTTGGATTTT-3'   | 55 (5), 53 (5),                | EcoRI              |
|        | GM4 5'-TTCCTTACRCCCTAAAACTTCC-3'   | 51(5), 49(26)                  |                    |
| 20     | Region 8 5'-GGGAGTTTGGGAGTTGATTTTGT-3'   | 60 (3), 58 (4),                | TaqI               |
|        | 5'-AACCAAATTAATAATCAACCCCTAA-3'  | 56 (5), 54 (26)                |                    |
|        | Region 8 5'-GAGGGGGGATYGTAAATTTTGT-3'  | 60 (3), 58 (4),                | BstUI              |
|        | 5'-CCRAATCTCTTATTATACCTCCAA-3'   | 56 (5), 54 (26)                |                    |
| 25     | Region 1 F/R=SEQ ID NO:33 and 34; Region 2=SEQ ID NO:35 and 36 and so forth through<br>Region 8 (TaqI)=SEQ ID NO:47 and 48 and Region 8 (BstUI)=SEQ ID NO:49 and 50. |                                |                    |

Exemplary target regions (i.e., regions 1-8 of MINT31/CACNA1G) that are complementary to the primers listed in Table 2 are provided in Table 3:

Table 3 - Target Sequences

| Region/<br>Primer | Target set, forward /reverse      | SEQ ID NO | Corresponding<br>Primer<br>SEQ ID NO |
|-------------------|-----------------------------------|-----------|--------------------------------------|
| Region 1          | 5'- AACAAAATAACTACTACRCCRTC-3'    | 87        | 33                                   |
| F165              | 5'- GTAAAGTGAGGGGTGGTGATG-3'      | 88        | 34                                   |
| Region 2          | 5'- CTCCAAAAAATAATAATACCRRAA-3'   | 89        | 35                                   |
| GM2               | 5'- GAGTGAGTGAAGGYGGTAGATT-3'     | 90        | 36                                   |
| Region 3          | 5'- AACCTCACATTAACRCTCCTAAA-3'    | 91        | 37                                   |
| GM3               | 5'- GTTTTTTTAAGATTGGGTTTTTTTAG-3' | 92        | 38                                   |
| Region 4          | 5'- CAAACCCCAACATCCTTTATCCA-3'    | 93        | 39                                   |
| GM5               | 5'- GGATTTAGGGGTAAGGGGAGGG-3'     | 94        | 40                                   |
| Region 5          | 5'- AAAAACCACAACATAAATCCRATT-3'   | 95        | 41                                   |
| GM1               | 5'- AGTGAGGGATTAGTTGTGGTGTG-3'    | 96        | 42                                   |
| Region 6          | 5'- AACTATCRCCAACRCCACAA-3'       | 97        | 43                                   |
| GM6               | 5'- AAGAGATTTTTTTTTTTTTTTTGT-3'   | 98        | 44                                   |
| Region 7          | 5'- AAAATCCRAAAAAAACRCCCCC-3'     | 99        | 45                                   |
| GM4               | 5'- GGAAGTTTATAGGGGYTAGGGGAA-3'   | 100       | 46                                   |
| Region 8          | 5'- AACAAAATACAACATCCCAACACCC-3'  | 101       | 47                                   |
|                   | 5'- TTAGGGTTTGATTTTTAAATTGGTT-3'  | 102       | 48                                   |
| Region 8          | 5'- CAAAAAATTACRATCCCCCTC-3'      | 103       | 49                                   |
|                   | 5'- TTGGAGGTATAATAAGGAGATTTTGG-3' | 104       | 50                                   |



TABLE 4 Targets for Bisulfite-PCR Primers

| Genes            |                               | SEQ ID NO | Corresponding<br>Primer<br>SEQ ID NO |
|------------------|-------------------------------|-----------|--------------------------------------|
| APOB 5'-target   | 5'-AAAAAACCCAACTACAAAAAC-3'   | 55        | 1                                    |
| 3'-target        | 5'-GTTGTTGGRGTTGTTGGR-3'      | 56        | 2                                    |
| R6 5'-target     | 5'-AACTATCYCCAACYCCACAA-3'    | 57        | 3                                    |
| 3'-target        | 5'-AAGAGATTTTTTTTTTTTTTTT-3'  | 58        | 4                                    |
| R7 5'-target     | 5'-AAAATCCYAAAAAAACCCCC-3'    | 59        | 5                                    |
| 3'-target        | 5'-GGAAGTTTTAGGGGRTAGGGGAA-3' | 60        | 6                                    |
| CDX2 5'-target   | 5'-AACATCCCTCCCTCTAACCTAC-3'  | 61        | 7                                    |
| 3'-target        | 5'-AGGTAGTATGGTGAGGTTGTTTT-3' | 62        | 8                                    |
| EGFR 5'-target   | 5'-ATCAATACTAAACRAAATCAAA-3'  | 63        | 9                                    |
| 3'-target        | 5'-AGGAAAAAGAAAGGTAAGGG-3'    | 64        | 10                                   |
| FBNI 5'-target   | 5'-CAAAATTAACRCAATAAAAAAA-3'  | 65        | 11                                   |
| 3'-target        | 5'-TATTTGAAGAGGTGGGGAAA-3'    | 66        | 12                                   |
| GPR37 5'-target  | 5'-AAACTCTTACCCCACTAACC-3'    | 67        | 13                                   |
| 3'-target        | 5'-GGTTTGAATTGGATTAAAYGTT-3'  | 68        | 14                                   |
| HSPA6 5'-target  | 5'-CCACTAACTCAAACTAAAAAA-3'   | 69        | 15                                   |
| 3'-target        | 5'-GGGAGGTGTAAAAGGATGAAA-3'   | 70        | 16                                   |
| IQGAP2 5'-target | 5'-CTAACCTAAAAATAAAATAAA-3'   | 71        | 17                                   |
| 3'-target        | 5'-GTAGGATGTTATAYGAAGAG-3'    | 72        | 18                                   |
| KL 5'-target     | 5'-AAACRCTAACRAACATACTAC-3'   | 73        | 19                                   |
| 3'-target        | 5'-GGGTTTTTTTAGGGTATTT-3'     | 74        | 20                                   |
| PAR2 5'-target   | 5'-GGGTTTTTTTAGGGTATTT-3'     | 75        | 21                                   |
| 3'-target        | 5'-TTTAGGAGGATGYGGAGTT-3'     | 76        | 22                                   |
| PITX2 5'-target  | 5'-AAAAACCTAACRAAACCTTA-3'    | 77        | 23                                   |
| 3'-target        | 5'-GTTATGTGTAGTGGAGTTTGG-3'   | 78        | 24                                   |
| PTCHA 5'-target  | 5'-ACTCCRAATTAACAAACCAAC-3'   | 79        | 25                                   |
| 3'-target        | 5'-AATATGGTTTYGGTTGGTAA-3'    | 80        | 26                                   |
| PTCHB 5'-target  | 5'-TCCCTAAATTCACACATT-3'      | 81        | 27                                   |
| 3'-target        | 5'-GTAAGTTGTAGTTGGTTGTTTA-3'  | 82        | 28                                   |
| SDC1 5'-target   | 5'-CTCTACTACCRAATTCCTCT-3'    | 83        | 29                                   |
| 3'-target        | 5'-GTTTGGTTTTGGTTGTG-3'       | 84        | 30                                   |
| SDC4 5'-target   | 5'-CCACTACCAACAAATCCCC-3'     | 85        | 31                                   |
| 3'-target        | 5'-TTTATTGGGGAATTCGGG-3'      | 86        | 32                                   |

Table 5 New genes differentially methylated in disease versus normal issue

| Gene Symbol             | Gene name                                      | Map     | Unigene Entry <sup>1</sup> | Methylated In <sup>2</sup>         |
|-------------------------|--|---------|----------------------------|------------------------------------|
| <i>APOB</i>             | Apolipoprotein B                               | 2p24    | Hs.585                     | Common Tumors                      |
| <i>CACNA1G</i>          | T-type calcium channel                         | 17      | -                          |                                    |
| <i>CDX2</i>             | Caudal type homeo box transcription factor 2   | 13q12,3 | Hs.77399                   | Leukemias, breast, prostate        |
| <i>EGFR</i>             | Epidermal Growth Factor Receptor               | 7p12    | Hs.77432                   | Leukemias, breast                  |
| <i>FBN1</i>             | Fibrillin-1                                    | 15q21.1 | Hs.750                     | Colon, Breast, prostate, leukemias |
| <i>GPR37</i>            | G protein-coupled receptor 37                  | 7q31    | Hs.27747                   | colon, breast, leukemias           |
| <i>HSPA6</i>            | Heat shock 70kD protein 6 (HSP70B')            | 1q      | Hs.3268                    | Common tumors                      |
| <i>IQGAP2</i>           | RasGAP-related protein                         | 5q      | Hs.78993                   | Common tumors                      |
| <i>KL</i>               | Klotho   | -       | Hs.94592                   | Common tumors                      |
| <i>PAR2</i>             | Proteinase-activated receptor 2                | 5q13    | Hs.154299                  | Leukemias, breast                  |
| <i>PITX2</i>            | Paired-like homeodomain transcription factor 2 | 4q25-27 | Hs.92282                   | Leukemias, prostate, breast        |
| <i>PTCH<sup>3</sup></i> | Patched  | 9Q31    | Hs.159526                  | Leukemias                          |
| <i>SDC1</i>             | Syndecan 1                                     | 2p24.1  | Hs.82109                   | Leukemias                          |
| <i>SDC4</i>             | Syndecan 4                                     | 20q12   | Hs.72082                   | Leukemias                          |

Table 5: New genes differentially methylated in cancer and other diseases.

<sup>1</sup> Gene database that can be found at <http://www.ncbi.nlm.nih.gov/UniGene/index.html>.<sup>2</sup> Examples: List is not comprehensive.<sup>3</sup> Two promoters are affected.

In another embodiment, detection of differential methylation is accomplished by contacting a nucleic acid sample suspected of comprising a CpG-containing nucleic acid with a methylation sensitive restriction endonuclease that cleaves only unmethylated CpG sites under conditions and for a time to allow cleavage of unmethylated nucleic acid. The sample is further contacted with an isoschizomer of the methylation sensitive restriction endonuclease, that cleaves both methylated and unmethylated CpG-sites, under conditions and for a time to allow cleavage of methylated nucleic acid. Oligonucleotides are added to the nucleic acid sample under conditions and for a time to allow ligation of the oligonucleotides to nucleic acid cleaved by the restriction endonuclease, and the digested nucleic acid is amplified by conventional methods such as PCR wherein primers complementary to the oligonucleotides are employed. Following identification, the methylated CpG-containing nucleic acid can be cloned, using method well known to one of skill in the art (see Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press, 1989).

As used herein, a "methylation sensitive restriction endonuclease" is a restriction endonuclease that includes CG as part of its recognition site and has altered activity when the C is methylated as compared to when the C is not methylated. Preferably, the methylation sensitive restriction endonuclease has inhibited activity when the C is methylated (e.g., SmaI). Specific non-limiting examples of a methylation sensitive restriction endonucleases include Sma I, BssHII, or HpaII. Such enzymes can be used alone or in combination. Other methylation sensitive restriction endonucleases will be known to those of skill in the art and include, but are not limited to SacII, EagI, and BstUI, for example. An "isoschizomer" of a methylation sensitive restriction endonuclease is a restriction endonuclease which recognizes the same recognition site as a methylation sensitive restriction endonuclease but which cleaves both methylated and unmethylated CGs. One of skill in the art can readily determine appropriate conditions for a restriction endonuclease to cleave a nucleic acid (see Sambrook et al., Molecular

Cloning: a Laboratory Manual, Cold Spring Harbor Press, 1989). Without being bound by theory, actively transcribed genes generally contain fewer methylated CGs than in other genes.

5           In one embodiment of the invention, a nucleic acid of interest is cleaved with a methylation sensitive endonuclease. In one aspect, cleavage with the methylation sensitive endonuclease creates a sufficient overhang on the nucleic acid of interest. Following cleavage with the isoschizomer, the cleavage product can still have a sufficient overhang. An "overhang" refers to nucleic acid having two strands wherein the  
10       strands end in such a manner that a few bases of one strand are not base paired to the other strand. A "sufficient overhang" refers to an overhang of sufficient length to allow specific hybridization of an oligonucleotide of interest. In one embodiment, a sufficient overhang is at least two bases in length. In another embodiment, the sufficient overhang is four or more bases in length. An overhang of a specific sequence on the nucleic acid of  
15       interest may be desired in order for an oligonucleotide of interest to hybridize. In this case, the isoschizomer can be used to create the overhang having the desired sequence on the nucleic acid of interest.

          In another aspect of this embodiment, the cleavage with a methylation sensitive  
20       endonuclease results in a reaction product of the nucleic acid of interest that has a blunt end or an insufficient overhang. In this embodiment, an isoschizomer of the methylation sensitive restriction endonuclease can create a sufficient overhang on the nucleic acid of interest. "Blunt ends" refers to a flush ending of two stands, the sense stand and the antisense strand, of a nucleic acid.

25           Once a sufficient overhang is created on the nucleic acid of interest, an oligonucleotide is ligated to the nucleic acid cleaved of interest which has been cleaved by the methylation specific restriction endonuclease. "Ligation" is the attachment of two

nucleic acid sequences by base pairing of substantially complementary sequences and/or by the formation of covalent bonds between two nucleic acid sequences. In one aspect of the present invention, an "oligonucleotide" is a nucleic acid sequence of about 2 up to about 40 bases in length. It is presently preferred that the oligonucleotide is from about  
5 15 to 35 bases in length.

In one embodiment, an adaptor is utilized to create DNA ends of desired sequence and overhang. An "adaptor" is a double-stranded nucleic acid sequence with one end that has a sufficient single-stranded overhang at one or both ends such that the adaptor can be  
10 ligated by base-pairing to a sufficient overhang on a nucleic acid of interest that has been cleaved by a methylation sensitive restriction enzyme or an isoschizomer of a methylation sensitive restriction enzyme. Adaptors can be obtained commercially, or two oligonucleotides can be utilized to form an adaptor. Thus, in one embodiment, two oligonucleotides are used to form an adaptor; these oligonucleotides are substantially  
15 complementary over their entire sequence except for the region(s) at the 5' and/or 3' ends that will form a single stranded overhang. The single stranded overhang is complementary to an overhang on the nucleic acid cleaved by a methylation sensitive restriction enzyme or an isoschizomer of a methylation sensitive restriction enzyme, such that the overhang on the nucleic acid of interest will base pair with the 3' or 5' single  
20 stranded end of the adaptor under appropriate conditions. The conditions will vary depending on the sequence composition (GC vs AT), the length, and the type of nucleic acid (see Sambrook et al., Molecular Cloning: a Laboratory Manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Plainview, NY, 1998).

25 Following the ligation of the oligonucleotide, the nucleic acid of interest is amplified using a primer complementary to the oligonucleotide. Specifically, the term "primer" as used herein refers to a sequence comprising two or more deoxyribo-nucleotides or ribonucleotides, preferably more than three, and more preferably more than

eight, wherein the sequence is capable of initiating synthesis of a primer extension product, which is substantially complementary to a nucleic acid such as an adaptor or a ligated oligonucleotide. Environmental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent for polymerization, such as DNA  
5 polymerase, and a suitable temperature and pH. The primer is preferably single stranded for maximum efficiency in amplification, but may be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. In one embodiment, the primer is an oligodeoxyribo-nucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the  
10 presence of the inducing agent for polymerization. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition. The oligonucleotide primer typically contains 12-20 or more nucleotides, although it may contain fewer nucleotides.

15 Primers of the invention are designed to be "substantially" complementary to each strand of the oligonucleotide to be amplified and include the appropriate G or C nucleotides as discussed above. This means that the primers must be sufficiently complementary to hybridize with their respective strands under conditions which allow the agent for polymerization to perform. In other words, the primers should have  
20 sufficient complementarity with a 5' and 3' oligonucleotide to hybridize therewith and permit amplification of CpG containing nucleic acid sequence.

Primers of the invention are employed in the amplification process which is an enzymatic chain reaction that produces exponential quantities of target locus relative to  
25 the number of reaction steps involved (e.g., polymerase chain reaction or PCR). Typically, one primer is complementary to the negative (-) strand of the locus and the other is complementary to the positive (+) strand. Annealing the primers to denatured nucleic acid followed by extension with an enzyme, such as the large fragment of DNA

Polymerase I (Klenow) and nucleotides, results in newly synthesized + and - strands containing the target locus sequence. Because these newly synthesized sequences are also templates, repeated cycles of denaturing, primer annealing, and extension results in exponential production of the region (i.e., the target locus sequence) defined by the primer. The product of the chain reaction is a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed.

The oligonucleotide primers of the invention may be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al. (Tetrahedron Letters, 22:1859-1862, 1981). One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Patent No. 4,458,066.

Where the CpG-containing nucleic acid sequence of interest contains two strands, it is necessary to separate the strands of the nucleic acid before it can be used as a template for the amplification process. Strand separation can be effected either as a separate step or simultaneously with the synthesis of the primer extension products. This strand separation can be accomplished using various suitable denaturing conditions, including physical, chemical, or enzymatic means, the word "denaturing" includes all such means. One physical method of separating nucleic acid strands involves heating the nucleic acid until it is denatured. Typical heat denaturation may involve temperatures ranging from about 80° to 105°C for times ranging from about 1 to 10 minutes. Strand separation may also be induced by an enzyme from the class of enzymes known as helicases or by the enzyme RecA, which has helicase activity, and in the presence of riboATP, is known to denature DNA. The reaction conditions suitable for strand separation of nucleic acids with helicases are described by Kuhn Hoffmann-Berling (CSH-Quantitative Biology, 43:63, 1978) and techniques for using RecA are reviewed in C. Radding (Ann. Rev. Genetics, 16:405-437, 1982).

When complementary strands of nucleic acid or acids are separated, regardless of whether the nucleic acid was originally double or single stranded, the separated strands are ready to be used as a template for the synthesis of additional nucleic acid strands.

- 5 This synthesis is performed under conditions allowing hybridization of primers to templates to occur. Generally synthesis occurs in a buffered aqueous solution, generally at a pH of about 7-9. Preferably, a molar excess (for genomic nucleic acid, usually about 108:1 primer:template) of the two oligonucleotide primers is added to the buffer containing the separated template strands. It is understood, however, that the amount of
- 10 complementary strand may not be known if the process of the invention is used for diagnostic applications, so that the amount of primer relative to the amount of complementary strand cannot be determined with certainty. As a practical matter, however, the amount of primer added will generally be in molar excess over the amount of complementary strand (template) when the sequence to be amplified is contained in a
- 15 mixture of complicated long-chain nucleic acid strands. a large molar excess is preferred to improve the efficiency of the process.

- The deoxyribonucleoside triphosphates dATP, dCTP, dGTP, and dTTP are added to the synthesis mixture, either separately or together with the primers, in adequate
- 20 amounts and the resulting solution is heated to about 90°-100°C from about 1 to 10 minutes, preferably from 1 to 4 minutes. After this heating period, the solution is allowed to cool to approximately room temperature, which is preferable for the primer hybridization. To the cooled mixture is added an appropriate agent for effecting the primer extension reaction (called herein "agent for polymerization"), and the reaction is
- 25 allowed to occur under conditions known in the art. The agent for polymerization may also be added together with the other reagents if it is heat stable. This synthesis (or amplification) reaction may occur at room temperature up to a temperature above which the agent for polymerization no longer functions. Thus, for example, if DNA polymerase



is used as the agent, the temperature is generally no greater than about 40°C. Most conveniently the reaction occurs at room temperature.

The agent for polymerization may be any compound or system which will  
5 function to accomplish the synthesis of primer extension products, including enzymes. Suitable enzymes for this purpose include, for example, E. coli DNA polymerase I, Klenow fragment of E. coli DNA polymerase I, T4 DNA polymerase, other available DNA polymerases, polymerase mutants, reverse transcriptase, and other enzymes,  
10 including heat-stable enzymes (i.e., those enzymes which perform primer extension after being subjected to temperatures sufficiently elevated to cause denaturation such as Taq DNA polymerase, and the like). Suitable enzymes will facilitate combination of the nucleotides in the proper manner to form the primer extension products which are complementary to each locus nucleic acid strand. Generally, the synthesis will be  
15 initiated at the 3' end of each primer and proceed in the 5' direction along the template strand, until synthesis terminates, producing molecules of different lengths. There may be agents for polymerization, however, which initiate synthesis at the 5' end and proceed in the other direction, using the same process as described above.

Preferably, the method of amplifying is by PCR, as described herein and as is  
20 commonly used by those of ordinary skill in the art. However, alternative methods of amplification have been described and can also be employed. PCR techniques and many variations of PCR are known. Basic PCR techniques are described by Saiki et al. (1988 Science 239:487-491) and by U.S. Pat. Nos. 4,683,195, 4,683,202 and 4,800,159, which are incorporated herein by reference.

25

The conditions generally required for PCR include temperature, salt, cation, pH and related conditions needed for efficient copying of the master-cut fragment. PCR conditions include repeated cycles of heat denaturation (i.e. heating to at least about 95.degree. C.) and incubation at a temperature permitting primer: adaptor hybridization

- and copying of the master-cut DNA fragment by the amplification enzyme. Heat stable amplification enzymes like the pwo, *Thermus aquaticus* or *Thermococcus litoralis* DNA polymerases are commercially available which eliminate the need to add enzyme after each denaturation cycle. The salt, cation, pH and related factors needed for enzymatic
- 5 amplification activity are available from commercial manufacturers of amplification enzymes.

- As provided herein an amplification enzyme is any enzyme which can be used for in vitro nucleic acid amplification, e.g. by the above-described procedures. Such
- 10 amplification enzymes include pwo, *Escherichia coli* DNA polymerase I, Klenow fragment of *E. coli* DNA polymerase I, T4 DNA polymerase, T7 DNA polymerase, *Thermus aquaticus* (Taq) DNA polymerase, *Thermococcus litoralis* DNA polymerase, SP6 RNA polymerase, T7 RNA polymerase, T3 RNA polymerase, T4 polynucleotide kinase, Avian Myeloblastosis Virus reverse transcriptase, Moloney Murine Leukemia
- 15 Virus reverse transcriptase, T4 DNA ligase, *E. coli* DNA ligase or Q.beta. replicase. Preferred amplification enzymes are the pwo and Taq polymerases. The pwo enzyme is especially preferred because of its fidelity in replicating DNA.

- Once amplified, the nucleic acid can be attached to a solid support, such as a
- 20 membrane, and can be hybridized with any probe of interest, to detect any nucleic acid sequence. Several membranes are known to one of skill in the art for the adhesion of nucleic acid sequences. Specific non-limiting examples of these membranes include nitrocellulose (NITROPURE) or other membranes used in for detection of gene expression such as polyvinylchloride, diazotized paper and other commercially available
- 25 membranes such as GENESCREEN, ZETAPROBE (Biorad), and NYTRAN Methods for attaching nucleic acids to these membranes are well known to one of skill in the art. Alternatively, screening can be done in a liquid phase.

In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (e.g., GC v. AT content), and nucleic acid type (e.g., RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). Washing can be carried out using only one of these conditions, e.g., high stringency conditions, or each of the conditions can be used, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically. In general, conditions of high stringency are used for the hybridization of the probe of interest.

The probe of interest can be detectably labeled, for example, with a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator, or an enzyme. Those of ordinary skill in the art will know of other suitable labels for binding to the probe, or will be able to ascertain such, using routine experimentation.

In one embodiment, representational difference analysis (RDA, see Lisitsyn et al., Science 259:946-951, 1993, herein incorporated by reference) can be performed on CpG-containing nucleic acid following MCA. MCA utilizes kinetic and subtractive

enrichment to purify restriction endonuclease fragments present in one population of nucleic acid fragments but not in another. Thus, RDA enables the identification of small differences between the sequences of two nucleic acid populations. RDA uses nucleic acid from one population as a "tester" and nucleic acid from a second population as a "driver" in order to clone probes for single copy sequences present in (or absent from) one of the two populations. In one embodiment, nucleic acid from a "normal" individual or sample, not having a disorder such as a cell-proliferative disorder is used as a "driver," and nucleic acid from an "affected" individual or sample, having the disorder such as a cell proliferative disorder is used as a "tester." In one embodiment, the nucleic acid used as a "tester" is isolated from an individual having a cell proliferative disorder such as low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, leukemia, lung cancer, renal cancer, breast cancer, prostate cancer, endometrial cancer and neuroblastoma. The nucleic acid used as a "driver" is thus normal astrocytes, normal glial cells, normal brain cells, normal gastric cells, normal colorectal cells, normal leukocytes, normal lung cells, normal kidney cells, normal breast cells, normal prostate cells, normal uterine cells, and normal neurons, respectively. In an additional embodiment, the nucleic acid used as a "driver" is isolated from an individual having a cell proliferative disorder such as low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, leukemia, lung cancer, renal cancer, breast cancer, prostate cancer, endometrial cancer and neuroblastoma. The nucleic acid used as a "tester" is thus normal astrocytes, normal glial cells, normal brain cells, normal gastric cells, normal colorectal cells, normal leukocytes, normal lung cells, normal kidney cells, normal breast cells, normal prostate cells, normal uterine cells, and normal neurons, respectively. One of skill in the art will readily be able to identify the "tester" nucleic acid useful with to identify methylated nucleic acid sequences in given "driver" population.

## KITS

The materials for use in the assay of the invention are ideally suited for the preparation of a kit. Therefore, in accordance with another embodiment of the present invention, there is provided a kit it useful for the detection of a cellular proliferative disorder in a subject having or at risk for said cellular proliferative disorder. Invention kits include a carrier means compartmentalized to receive a sample in close confinement therein, one or more containers comprising a first container containing a reagent which modifies unmethylated cytosine and a second container containing primers for amplification of a CpG-containing nucleic acid, wherein the primers distinguish between modified methylated and nonmethylated nucleic acid, and optionally, a third container containing a methylation sensitive restriction endonuclease. Primers contemplated for use in accordance with the invention include those set forth in SEQ ID NOs: 1-50.

Carrier means are suited for containing one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. In view of the description provided herein of invention methods, those of skill in the art can readily determine the apportionment of the necessary reagents among the container means. For example, one of the container means can comprise a container containing an oligonucleotide for ligation to nucleic acid cleaved by a methylation sensitive restriction endonuclease. One or more container means can also be included comprising a primer complementary to the oligonucleotide. In addition, one or more container means can also be included which comprise a methylation sensitive restriction endonuclease. One or more container means can also be included containing an isoschizomer of said methylation sensitive restriction enzyme.

25

In another embodiment, the kit may comprise a carrier means containing one or more container means comprising a solid support, wherein the solid support has a nucleic acid sequence of CACNA1G as described herein immobilized on the solid support. In

one embodiment, the solid support is a membrane. Several membranes are known to one of skill in the art for the adhesion of nucleic acid sequences. Specific non-limiting examples of these membranes include nitrocellulose (Nitropure) or other membranes used in for detection of gene expression such as polyvinylchloride, diazotized paper and other commercially available membranes such as GENESCREEN, ZETAPROBE (Biorad), and NYTRAN. The CACNA1G sequences immobilized on the solid support can then be hybridized to nucleic acid sequences produced by performing the MCA procedure, bisulfite PCR or other methylation detection methods on the nucleic acids of a sample of interest in order to determine if the nucleic acid sequences contained in the sample are methylated.

The term "oligonucleotide primer" refers to a sequence of two or more deoxyribonucleotides or ribonucleotides, preferably at least eight, which sequence is capable of initiating synthesis of a primer extension product that is substantially complementary to a target nucleic acid strand. The oligonucleotide primer typically contains fifteen to twenty-two or more nucleotides, although it may contain fewer nucleotides if the primer is complementary, so as to specifically allow the amplification of the specifically desired target nucleotide sequence.

The oligonucleotide primers for use in the invention may be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated embodiment, diethyl-phosphoramidites are used as starting materials and may be synthesized as described by Beaucage et al., Tetrahedron Letter, 22: 1859-1862 (1981). One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Patent No. 4,458,066. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition. The primer must prime the synthesis of extension products in the presence of the inducing agent for amplification.

Primers used according to the method of the invention are complementary to each strand of mutant nucleotide sequence to be amplified. The term "complementary" means that the primers must hybridize with their respective strands under conditions which allow the agent for polymerization to function. In other words, the primers that are  
5 complementary to the flanking sequences hybridize with the flanking sequences and permit amplification of the nucleotide sequence. Preferably, the 3' terminus of the primer that is extended has perfectly base paired complementarity with the complementary flanking strand.

10 The term "flanks CpG-rich regions" refers to those DNA sequences on chromosome that are upstream (5') or downstream (3') to the DNA sequence to be amplified. The sequence to be amplified is preferably a CpG-rich region in a gene or regulatory region associated with a gene. For example, when the nucleotide sequence to be amplified is double stranded, a first sequence that is 5' to the nucleotide sequence and  
15 a second sequence that is 5' to the nucleotide sequence on the complementary strand flank the CpG-rich DNA sequence.

The nucleotide sequences that flank nucleotide repeats, i.e., the nucleotide sequences to which the oligonucleotide primers hybridize, may be selected from among  
20 the following nucleotide sequences: SEQ ID NO:1-50.

In general, the primers used according to the method of the invention embrace oligonucleotides of sufficient length and appropriate sequence which provide specific initiation of polymerization of a significant number of nucleic acid molecules containing  
25 the target nucleic acid under the conditions of stringency for the reaction utilizing the primers. In this manner, it is possible to selectively amplify the specific target nucleic acid sequence containing the nucleic acid of interest. Oligonucleotide primers used according to the invention are employed in any amplification process that produces increased quantities of target nucleic acid.

The invention includes antibodies immunoreactive with CACNA1G polypeptide or functional fragments thereof. Antibody which consists essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided. Monoclonal antibodies are made from antigen containing fragments of the protein by methods well known to those skilled in the art (Kohler, *et al.*, *Nature*, 256:495, 1975). The term antibody as used in this invention is meant to include intact molecules as well as fragments thereof, such as Fab and F(ab')<sub>2</sub>, Fv and SCA fragments which are capable of binding an epitopic determinant on CACNA1G .

(1) An Fab fragment consists of a monovalent antigen-binding fragment of an antibody molecule, and can be produced by digestion of a whole antibody molecule with the enzyme papain, to yield a fragment consisting of an intact light chain and a portion of a heavy chain.

(2) An Fab' fragment of an antibody molecule can be obtained by treating a whole antibody molecule with pepsin, followed by reduction, to yield a molecule consisting of an intact light chain and a portion of a heavy chain. Two Fab' fragments are obtained per antibody molecule treated in this manner.

(3) An (Fab')<sub>2</sub> fragment of an antibody can be obtained by treating a whole antibody molecule with the enzyme pepsin, without subsequent reduction. A (Fab')<sub>2</sub> fragment is a dimer of two Fab' fragments, held together by two disulfide bonds.

(4) An Fv fragment is defined as a genetically engineered fragment containing the variable region of a light chain and the variable region of a heavy chain expressed as two chains.



(5) A single chain antibody ("SCA") is a genetically engineered single chain molecule containing the variable region of a light chain and the variable region of a heavy chain, linked by a suitable, flexible polypeptide linker.

5

As used in this invention, the term "epitope" refers to an antigenic determinant on an antigen, such as a CACNA1G polypeptide, to which the paratope of an antibody, such as an CACNA1G -specific antibody, binds. Antigenic determinants usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three-dimensional structural characteristics, as well as specific charge characteristics.

As is mentioned above, antigens that can be used in producing CACNA1G -specific antibodies include CACNA1G polypeptides or CACNA1G polypeptide fragments. The polypeptide or peptide used to immunize an animal can be obtained by standard recombinant, chemical synthetic, or purification methods. As is well known in the art, in order to increase immunogenicity, an antigen can be conjugated to a carrier protein. Commonly used carriers include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize the animal (*e.g.*, a mouse, a rat, or a rabbit). In addition to such carriers, well known adjuvants can be administered with the antigen to facilitate induction of a strong immune response.

The invention also provides a method for detecting a cell proliferative disorder associated with CACNA1G in a subject, comprising contacting a target cellular component suspected of having a CACNA1G associated disorder, with a reagent which reacts with or binds to CACNA1G and detecting CACNA1G. The target cell component can be nucleic acid, such as DNA or RNA, or it can be protein. When the component is

nucleic acid, the reagent is typically a nucleic acid probe or PCR primer. When the cell component is protein, the reagent is typically an antibody probe. The target cell component may be detected directly in situ or it may be isolated from other cell components by common methods known to those of skill in the art before contacting with a probe. (See for example, Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. 1989; Current Protocols in Molecular Biology, 1994, Ed. Ausubel, et al., Green Publ. Assoc. & Wiley Interscience.) Detection methods include Southern and Northern blot analyses, RNase protection, immunoassays and other detection assays that are known to those of skill in the art.

10

The probes can be detectably labeled, for example, with a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator, or an enzyme. Those of ordinary skill in the art will know of other suitable labels for binding to the probes or will be able to ascertain such, using routine experimentation.

15

Since the present invention shows that a decreased level of CACNA1G transcription is often the result of hypermethylation of the CACNA1G gene, it is often desirable to directly determine whether the CACNA1G gene is hypermethylated. In particular, the cytosine rich areas terms "CpG islands" which lie in the 5' regulatory regions of genes are normally unmethylated. The term "hypermethylation" includes any methylation of cytosine which is normally unmethylated in the CACNA1G gene sequence can be detected by restriction endonuclease treatment of CACNA1G polynucleotide (gene) and Southern blot analysis for example. Therefore, in a method of the invention, when the cellular component detected is DNA, restriction endonuclease analysis is preferable to detect hypermethylation of the CACNA1G gene. Any restriction endonuclease that includes CG as part of its recognition site and that is inhibited when the C is methylated, can be utilized. Methylation sensitive restriction endonucleases such as

20

25

BssHII, MspI, NotI or HpaII, used alone or in combination are examples of such endonucleases. Other methylation sensitive restriction endonucleases will be known to those of skill in the art. In addition, PCR can be utilized to detect the methylation status of the CACNA1G gene. Oligonucleotide primers based on any coding sequence region in the CACNA1G sequence are useful for amplifying DNA by PCR. CACNA1G is described here for exemplary purposes. The other genes described herein as being

For purposes of the invention, an antibody or nucleic acid probe specific for CACNA1G may be used to detect the presence of CACNA1G polypeptide (using antibody) or polynucleotide (using nucleic acid probe) in biological fluids or tissues. Oligonucleotide primers based on any coding sequence region in the CACNA1G sequence are useful for amplifying DNA, for example by PCR. Any specimen containing a detectable amount of CACNA1G polynucleotide or CACNA1G polypeptide antigen can be used. Nucleic acid can also be analyzed by RNA in situ methods which are known to those of skill in the art. A preferred sample of this invention is tissue of heart, renal, brain, colon, breast, urogenital, uterine, hematopoietic, prostate, thymus, lung, testis, and ovarian. Preferably the subject is human.

Various disorders which are detectable by the method of the invention include astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, colon cancer, lung cancer, renal cancer, leukemia, breast cancer, prostate cancer, endometrial cancer and neuroblastoma.

Monoclonal antibodies used in the method of the invention are suited for use, for example, in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. In addition, the monoclonal antibodies in these immunoassays can be detectably labeled in various ways. Examples of types of immunoassays which can utilize monoclonal antibodies of the invention are competitive and non-competitive

immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay. Detection of the antigens using the monoclonal antibodies of the invention can be done utilizing immunoassays which are run in either the forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

The term "immunometric assay" or "sandwich immunoassay", includes simultaneous sandwich, forward sandwich and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that antibodies according to the present invention will be useful in other variations and forms of assays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention.

Monoclonal antibodies can be bound to many different carriers and used to detect the presence of CACNA1G. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding monoclonal antibodies, or will be able to ascertain such using routine experimentation.

In performing the assays it may be desirable to include certain "blockers" in the incubation medium (usually added with the labeled soluble antibody). The "blockers" are added to assure that non-specific proteins, proteases, or anti-heterophilic immunoglobulins to anti-CACNA1G immunoglobulins present in the experimental sample do not cross-link or destroy the antibodies on the solid phase support, or the

radiolabeled indicator antibody, to yield false positive or false negative results. The selection of "blockers" therefore may add substantially to the specificity of the assays described in the present invention.

- 5 It has been found that a number of nonrelevant (i.e., nonspecific) antibodies of the same class or subclass (isotype) as those used in the assays (e.g., IgG1, IgG2a, IgM, etc.) can be used as "blockers". The concentration of the "blockers" (normally 1-100  $\mu\text{g}/\mu\text{l}$ ) may be important, in order to maintain the proper sensitivity yet inhibit any unwanted interference by mutually occurring cross reactive proteins in the specimen.

10

- In using a monoclonal antibody for the in vivo detection of antigen, the detectably labeled monoclonal antibody is given in a dose which is diagnostically effective. The term "diagnostically effective" means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the CACNA1G antigen for which the monoclonal antibodies are specific. The concentration of detectably labeled monoclonal antibody which is administered should be sufficient such that the binding to those cells having CACNA1G is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio.
- 15
- 20

- As a rule, the dosage of detectably labeled monoclonal antibody for in vivo diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual. The dosage of monoclonal antibody can vary from about 0.001 mg/m.sup.2 to about 500 mg/m.sup.2, preferably 0.1 mg/m.sup.2 to about 200 mg/m.sup.2, most preferably about 0.1 mg/m.sup.2 to about 10 mg/m.sup.2. Such dosages may vary, for example, depending on whether multiple injections are given, tumor burden, and other factors known to those of skill in the art.
- 25

For in vivo diagnostic imaging, the type of detection instrument available is a major factor in selecting a given radioisotope. The radioisotope chosen must have a type of decay which is detectable for a given type of instrument. Still another important factor in selecting a radioisotope for in vivo diagnosis is that the half-life of the radioisotope be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that deleterious radiation with respect to the host is minimized. Ideally, a radioisotope used for in vivo imaging will lack a particle emission, but produce a large number of photons in the 140-250 keV range, which may be readily detected by conventional gamma cameras.

For in vivo diagnosis, radioisotopes may be bound to immunoglobulin either directly or indirectly by using an intermediate functional group. Intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to immunoglobulins are the bifunctional chelating agents such as diethylenetriaminepentaacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules. Typical examples of metallic ions which can be bound to the monoclonal antibodies of the invention are  $^{111}\text{In}$ ,  $^{97}\text{Ru}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{72}\text{As}$ ,  $^{89}\text{Zr}$ , and  $^{201}\text{Tl}$ .

A monoclonal antibody useful in the method of the invention can also be labeled with a paramagnetic isotope for purposes of in vivo diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR). In general, any conventional method for visualizing diagnostic imaging can be utilized. Usually gamma and positron emitting radioisotopes are used for camera imaging and paramagnetic isotopes for MRI. Elements which are particularly useful in such techniques include  $^{157}\text{Gd}$ ,  $^{55}\text{Mn}$ ,  $^{162}\text{Dy}$ ,  $^{52}\text{Cr}$ , and  $^{56}\text{Fe}$ .

The present invention also provides a method for treating a subject with a cell proliferative disorder associated with of CACNA1G comprising administering to a subject with the disorder a therapeutically effective amount of reagent which modulates CACNA1G expression. In brain, breast and renal cancer cells, for example, the CACNA1G nucleotide sequence is under-expressed as compared to expression in a normal cell, therefore, it is possible to design appropriate therapeutic or diagnostic techniques directed to this sequence. Thus, where a cell-proliferative disorder is associated with the expression of CACNA1G associated with malignancy, nucleic acid sequences that modulate CACNA1G expression at the transcriptional or translational level can be used. In cases when a cell proliferative disorder or abnormal cell phenotype is associated with the under expression of CACNA1G, for example, nucleic acid sequences encoding CACNA1G (sense) could be administered to the subject with the disorder.

The term "cell-proliferative disorder" denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologically and genotypically. Such disorders may be associated, for example, with absence of expression of CACNA1G. Essentially, any disorder which is etiologically linked to expression of CACNA1G could be considered susceptible to treatment with a reagent of the invention which modulates CACNA1G expression.

The term "modulate" envisions the suppression of methylation of CACNA1G polynucleotide when CACNA1G is under-expressed. When a cell proliferative disorder is associated with CACNA1G expression, such methylation suppressive reagents as 5-azacytadine can be introduced to a cell. Alternatively, when a cell proliferative disorder is associated with under-expression of CACNA1G polypeptide, a sense polynucleotide sequence (the DNA coding strand) encoding CACNA1G polypeptide, or 5' regulatory nucleotide sequences (i.e., promoter) of CACNA1G in operable linkage with CACNA1G

polynucleotide can be introduced into the cell. Demethylases known in the art could also be used to remove methylation.

The present invention also provides gene therapy for the treatment of cell  
5 proliferative disorders which are mediated by CACNA1G . Such therapy would achieve  
its therapeutic effect by introduction of the appropriate CACNA1G polynucleotide which  
contains a CACNA1G structural gene (sense), into cells of subjects having the  
proliferative disorder. Delivery of sense CACNA1G polynucleotide constructs can be  
achieved using a recombinant expression vector such as a chimeric virus or a colloidal  
10 dispersion system.

The polynucleotide sequences used in the method of the invention may be the  
native, unmethylated sequence or, alternatively, may be a sequence in which a  
nonmethylatable analog is substituted within the sequence. Preferably, the analog is a  
15 nonmethylatable analog of cytidine, such as 5-azacytidine. Other analogs will be known  
to those of skill in the art. Alternatively, such nonmethylatable analogs could be  
administered to a subject as drug therapy, alone or simultaneously with a sense structural  
gene for CACNA1G or sense promoter for CACNA1G operably linked to CACNA1G  
structural gene.

20

In another embodiment, a CACNA1G structural gene is operably linked to a  
tissue specific heterologous promoter and used for gene therapy. For example, a  
CACNA1G gene can be ligated to prostate specific antigen (PSA)-prostate specific  
promoter for expression of CACNA1G in prostate tissue. Other tissue specific promoters  
25 will be known to those of skill in the art. Alternatively, the promoter for a tumor  
suppressor gene can be linked to the CACNA1G structural gene and used for gene  
therapy.



Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but  
 5 are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). Most preferably, a non-human primate retroviral vector is employed, such as the gibbon ape leukemia virus (GaLV), thereby providing a broader host range than murine vectors, for example.

10

A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. Retroviral vectors can be made target specific by inserting, for example, a polynucleotide encoding a sugar, a glycolipid, or a protein.  
 15 Preferred targeting is accomplished by using an antibody to target the retroviral vector. Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences which can be inserted into the retroviral genome to allow target specific delivery of the retroviral vector containing the CACNA1G sense or antisense polynucleotide.

20

Since recombinant retroviruses are defective, they require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are  
 25 missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for encapsidation. Helper cell lines which have deletions of the packaging signal include but are not limited to .PSI.2, PA317 and PA12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is

introduced into such cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion produced.

- 5           Another targeted delivery system for CACNA1G polynucleotide is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful  
10 as delivery vehicles in vitro and in vivo. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0  $\mu\text{m}$  can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., Trends Biochem. Sci., 6:77, 1981). In addition to mammalian cells,  
15 liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4)  
20 accurate and effective expression of genetic information (Mannino, et al., Biotechniques, 6:682, 1988).

- 25           The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly  
5 useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

10 The targeting of liposomes has been classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system  
15 (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

20

The surface of the targeted delivery system may be modified in a variety of ways. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the  
25 lipid chains to the targeting ligand.

In general, the compounds bound to the surface of the targeted delivery system will be ligands and receptors which will allow the targeted delivery system to find and

"home in" on the desired cells. A ligand may be any compound of interest which will bind to another compound, such as a receptor.

In general, surface membrane proteins which bind to specific effector molecules are referred to as receptors. In the present invention, antibodies are preferred receptors. Antibodies can be used to target liposomes to specific cell-surface ligands. For example, certain antigens expressed specifically on tumor cells, referred to as tumor-associated antigens (TAAs), may be exploited for the purpose of targeting CACNA1G antibody-containing liposomes directly to the malignant tumor. Since the CACNA1G gene product may be indiscriminate with respect to cell type in its action, a targeted delivery system offers a significant improvement over randomly injecting non-specific liposomes. Preferably, the target tissue is human brain, colon, breast, lung, and renal origin. A number of procedures can be used to covalently attach either polyclonal or monoclonal antibodies to a liposome bilayer. Antibody-targeted liposomes can include monoclonal or polyclonal antibodies or fragments thereof such as Fab, or F(ab').sub.2, as long as they bind efficiently to an antigenic epitope on the target cells. Liposomes may also be targeted to cells expressing receptors for hormones or other serum factors.

It should be noted that as used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the restriction enzyme" includes reference to one or more restriction enzymes and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to

those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

5 All publications mentioned herein are incorporated herein by reference in full for the purpose of describing and disclosing the methodologies which are described in the publications which might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure  
10 by virtue of prior invention.

The following example is intended to illustrate but not to limit the invention in any manner, shape, or form, either explicitly or implicitly. While they are typical of those that might be used, other procedures, methodologies, or techniques known to those  
15 skilled in the art may alternatively be used.

**EXAMPLE 1**  
**IDENTIFICATION OF CACNA1G AS A TARGET FOR**  
**HYPERMETHYLATION ON HUMAN CHROMOSOME 17q21**

20 In order to isolate genes differentially methylated in cancer cells as opposed to non-cancerous cells the following experimental protocols were used. An example of the results obtained is provided hereinabove in the description of the isolation and characterization of human CACNA1G.

25 Tissue Samples and Cell Lines

Forty-nine primary colorectal cancers, 28 colorectal adenomas, 16 primary gastric cancers and 17 acute myelogenous leukemia samples were used for methylation analyses.

DNA from eight colon cancer cell lines (Caco2, RKO, SW48, HCT116, DLD1, Lovo, SW837, HT29), 4 lung cancer cell lines (OH3, H249, H157, H209), 4 glioblastoma cell lines (Dauy, D283, U87, U373), 8 breast cancer cell lines (MB-468, MCF7, MB-231, MB-474, MB-435, MB-453, BT20, CAMA1, SKBR3), 7 hematopoietic tumor cell lines (CEM, Raji, KG1A, HL60, ML-1, MoIt3, K562), and 4 prostate cancer cell lines (DU145, DUPRO, LNCAP, TSUPRL) were also investigated. DNA was extracted by standard procedures. RNA was isolated from cell lines and adenomas using TRIZOL (GIBCO-BRL). For re-expression analysis, cell lines were treated with 5-Aza-deoxycytidine (SIGMA) at a final concentration of 1 M for 6 days. All tissue samples were obtained from patients who gave informed consent according to institutional guidelines.

#### RT-PCR.

Six g of total RNA, was reverse transcribed using the SUPERScript kit (GIBCO-BRL) for first strand cDNA synthesis. One hundred ng of cDNA was used as template for RT-PCR reactions. To design the RT-PCR primers, Blast search was performed using the rat Cacna1G cDNA sequence (Genbank AF027984) reported previously (25) and exon-intron boundaries of the human CACNA1G were predicted by this analysis. Each primer set was designed to amplify the cDNA across several introns. Primer sequences and PCR conditions are available, at <http://www.med.jhu.edu/methylation/primers>. GAPDH was also amplified as a control using primers GAPDHF: 5'-CGGAGTCAACGGATTGGTCGTAT-3' (SEQ ID NO:55) and GAPDHR: 5'-AGCCTTCTCCATGGTGGTGAAGAC-3' (SEQ ID NO:56). All reactions were performed with RT(-) controls. PCR amplification was performed for 35 cycles of 95° C 30 sec, 60-65°C for 30 sec, 72°C for 30 sec, and the products were analyzed by agarose gel electrophoresis.

#### DNA Sequencing and Data Analysis.

- PCR reaction products were precipitated with ethanol, resuspended in diluted water and cloned into the pCR2.1 vector using the TA cloning kit (Invitrogen) according to the manufacturer's instruction. After transformation, plasmid DNA was purified using the Wizard Miniprep Kit (Promega). DNA sequence analysis was carried out at the Johns
- 5 Hopkins University Sequence Facility using automated DNA sequencers (Applied Biosystems). Sequence homology was identified by the BLAST program of the National Center for Biological Information (NCBI) available at <http://www.ncbi.nlm.nih.gov/BLAST/>. An IMAGE cDNA clone (Genbank: H13333) was identified by BLAST analysis using the sequence of BAC AC004590 (Genbank) which includes MINT31.
  - 10 Putative genes (G1 and G2) were identified by GENSCAN (available at <http://ccr-081.mit.edu/GENSCANMIT.html>) using the BAC sequence data. IMAGE cDNA clone H1333) was then obtained from the American Type Culture Collection and completely sequenced. Potential transcription factor binding sites and promoter prediction were examined using the TESS and TSSG programs respectively, available at the Baylor
  - 15 College of Medicine BCM Launcher ([http://kiwi.imgen.bcm.tmc.edu:8088/search\\_launcher/launcher.html/](http://kiwi.imgen.bcm.tmc.edu:8088/search_launcher/launcher.html/)). The nucleotide sequence of part of the 5' end of the cDNA of CACNA1G has been submitted to Genbank.

#### Bisulfite-PCR Methylation Analysis.

- 20 Bisulfite treatment was performed as reports previously. (Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. and Baylin, S.B. Proc. Natl. Acad. Sci. USA. 93:9821-9826, 1996). Briefly, 2 g of genomic DNA was denatured with 2 M NaOH for 10 min., followed by incubation with 3 M Na-bisulfite, pH 5.0 for 16 hours at 50°C. After treatment DNA was purified using a Wizard Miniprep Column (Promega), precipitated
- 25 with ethanol and resuspended in 20 l of diluted water. Two l of the aliquot was used as template for each PCR reaction. Semi-quantitative bisulfite-PCR was performed essentially as described. Xiong, Z. and Laird, P. W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25:2532-2534, 1997. To avoid

overestimation of the methylated alleles, the following points were considered. First, primers were designed to contain a minimum number of CpG dinucleotides in the sequence to avoid the biased amplification of methylated alleles. If primers do contain CpG sites, they were designed to amplify methylated and unmethylated alleles equally (using a mixture of C or T for sense and a mixture of G or A for antisense primers). Second, the primers were designed to contain a maximum number of thymidines converted from cytosines to avoid amplifying the non-converted genomic sequence. Third, restriction sites which only appear after bisulfite conversion (e.g. ACGC to ACGT) were used (regions 1-8). PCR was performed as described previously (Herman, supra). Primer sequences, annealing temperature and PCR cycles are available at <http://www.jhu.edu/methylation/primers>. Twenty % of the PCR products were digested with the appropriate restriction enzymes, precipitated with ethanol and separated by 5% polysacrylamide gel electrophoresis. Gels were stained with ethidium bromide, and the intensity of each allele was calculated by densitometry, using the Image Quant software (Molecular Dynamics).

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.



What is claimed is:

1. An isolated nucleic acid molecule comprising the coding region for a T-type calcium channel and regulatory sequences associated therewith.
2. The nucleic acid molecule of claim 1, wherein said associated regulatory sequences contain CpG-rich regions.
3. The nucleic acid molecule of claim 2, wherein the state of methylation of the CpG-rich regions is determinative of the presence of a cellular proliferative disorder in a subject from which the nucleic acid molecule is isolated.
4. The nucleic acid molecule of claim 2, wherein hypermethylation of said CpG islands is indicative of the presence of a cellular proliferative disorder in a subject from which said nucleic acid is isolated.
5. The nucleic acid molecule of claim 1, wherein said T-type calcium channel is CACNA1G.
6. The nucleic acid molecule of claim 5, wherein said nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 51.
7. The nucleic acid molecule of claim 6, wherein one or more of regions 1-8 comprises methylated bases.
8. A substantially purified polypeptide encoded by the polynucleotide of SEQ ID NO:51.

9. The polypeptide of claim 8, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:52.
10. A method for detecting a cellular proliferative disorder in a subject comprising:
  - a) contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene; and
  - b) identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having said cellular proliferative, thereby detecting a cellular proliferative disorder in the subject.
11. The method of claim 10, wherein the regions of said gene are contained within CpG rich regions.
12. The method of claim 10, wherein the gene is selected from the group consisting of APOB, CACNA1G, CDX2, EGFR, FBN1, GPR37, HSPA6, IQGAP2, KL, PAR2, PITX2, PTCH, SDC1, SDC4 and combinations thereof.
13. The method of claim 10, wherein aberrant methylation comprises hypermethylation when compared to the same regions of the gene or associated regulatory regions in a subject not having the cellular proliferative disorder.
14. The method of claim 13, wherein the regions comprise regulatory regions of CACNA1G.
15. The method of claim 14, wherein the regions comprise regions 1-8 of CACNA1G.

16. The method of claim 15, wherein the regions comprise regions 1-2 of CACNA1G.
17. The method of claim 15, wherein the regions comprise regions 5-7 of CACNA1G.
18. The method of claim 15, wherein the regions comprise regions 4 and 8 of CACNA1G.
19. The method of claim 10, wherein the agent is a pair of primers that hybridize with a target sequence in the gene or associated regulatory region of the gene.
20. The method of claim 19, wherein the primers hybridize with a target polynucleotide sequence having the sequence selected from the group consisting of SEQ ID NO:55-103 and SEQ ID NO:104.
21. The method of claim 20, wherein the primers are in consecutive pairs selected from the group consisting of SEQ ID NO:1-49 and SEQ ID NO:50.
22. The method of claim 10, wherein the nucleic acid-containing specimen comprises a tissue selected from the group consisting of brain, colon, urogenital, lung, renal, prostate, pancreas, liver, esophagus, stomach, hematopoietic, breast, thymus, testis, ovarian, and uterine.
23. The method of claim 10, wherein the nucleic acid-containing specimen is selected from the group consisting of serum, urine, saliva, blood, cerebrospinal fluid, pleural fluid, ascites fluid, sputum, stool, and biopsy sample.

24. The method of claim 10, wherein said cellular proliferative disorder is selected from the group consisting of low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, gastric cancer, colorectal cancer, colorectal adenoma, acute myelogenous leukemia, lung cancer, renal cancer, leukemia, breast cancer, prostate cancer, endometrial cancer and neuroblastoma.
25. A kit useful for the detection of a cellular proliferative disorder in a subject comprising:
- a) carrier means compartmentalized to receive a sample therein;
  - b) one or more containers comprising a first container containing a reagent which modifies unmethylated cytosine and a second container containing primers for amplification of a CpG-containing nucleic acid, wherein the primer hybridizes with a target polynucleotide sequence having the sequence selected from the group consisting of SEQ ID NO:55-103 and SEQ ID NO:104.
26. The kit of claim 25, further comprising a third container containing a methylation sensitive restriction endonuclease.
27. The kit of claim 25, wherein said modifying reagent is bisulfite.
28. The kit of claim 25, wherein the primers are selected from the group consisting of SEQ ID NO:1-49 and SEQ ID NO:50.
29. Isolated oligonucleotide primer(s) for detection of a methylated CpG-containing nucleic acid wherein the primer hybridizes with a target polynucleotide sequence having the sequence selected from the group consisting of SEQ ID NO:55-103 and SEQ ID NO:104.

30. The primers of claim 29, wherein said primers are selected from the group consisting of SEQ ID NO:1-49 and SEQ ID NO:50.

31. An isolated nucleic acid molecule having at least one methylated Cytosine of a CpG dinucleotide in a CpG-rich region and encoding a gene selected from the group consisting of APOB, CACNA1G, CDX2, EGFR, FBN1, GPR37, HSPA6, IQGAP2, KL, PAR2, PITX2, PTCH, SDC1, and SDC4.

32. The nucleic acid molecule of claim 31, wherein the methylated C residue of a CpG dinucleotide is located within a CpG-rich region selected from the group consisting of SEQ ID NO:105-118 and SEQ ID NO:119.

**ABSTRACT OF THE INVENTION**

A novel T-type calcium channel (CACNA1G) is provided, as are polynucleotides encoding the same. CACNA1G has been implicated in cellular proliferative disorders. More specifically, it has been observed that the methylation state of specific regions within CpG islands associated with the CACNA1G gene correlates with a number of cancerous phenotypes involving a variety of tissue and cell types. Also provided are methods for detecting cellular proliferative disorders by determining the methylation state of genes or regulatory regions associated therewith, including CACNA1G, as well as kits containing reagents for performing invention methods.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205

Figure 1A



Figure 1B




Figure 2






FIGURE 3A (SEQ ID NO:51) CACNA1G nucleotide sequence

CCTTTTCGTTGCGCCTCTCGGGGCGGCTTCGCCGAAGGTAGCGCCGAATCCGGCAACCCGGAGCCTGGGCGCGAAGCGAAG  
 AAGCCGGAAACAAAGTGGAGGGGAGCGCGCGGCTGGCCCCGGAAGCCCGAGGGGCGAAGCGGGAATCGCGCGCG  
 GCGGGGTTTCCTCGCGCCCCCGCGCCCCGCGGCGAGCATGCCCTCGGGGCGAGGGAGAGCTGGGCTGAACCTGGCCCTCCC  
 GGGGGCTCAGCTTGCGCCCTAGAGCCACAGATGTGCCCCCGCGGGCCCCGGTTGGCTGAGGACACCTCCTCTGA  
 GGGGCGCGCTTGCCCTCTCCGGATCGCGGGGCCCCGGCTGGCCAGAGGATGGACGAGGAGGAGGATGGAGCGGGCG  
 CCGAGGAGTCCGGGACAGCCCCGGAGCTTCATGCGGCTCAACGACCTGTGCGGGGCGGGGGCGGCGCGGGGCGGGGTCA  
 GCAGAAAAGGACCCGGGCGAGCGCGACTCCGAGGCGGAGGGGCTGCCGTACCCGGCGCTGGCCCGGCTGTTTCTTCTA  
 CTTGAGCCAGGACAGCGCCCGCGGAGCTGTGTCTCCGCGACGGTCTGAACCCCTGGTTGAGCGCATCAGCATGTTGG  
 TCATCCTTCTCAACTGCGTGACCCCTGGGCGATGTTCCGGCCATGCGAGGACATCGCTGTGACTCCACAGCGCTGCCGGATC  
 CTGCGAGCCTTGTGATGACTTCATCTTTGCCCTCTTTGCGGTGAGAGATGGTGGTGAAGATGGTGCCCTTGGGCGATCTTTGG  
 GAAAAGTGTACCTGGGAGACACTGGAACCGGCTTGACTTTTTCATCGTCATCGCAGGGATCTGAGGACTCTCGCTGG  
 ACCTGCAGAACTGCTCAGCTTCTCAGCTGTGAGGACAGTCCGTGTGCTGCGACCGCTCAGGGCCATTACCGGGTGCCCGAG  
 ATGCGCATCCCTTGCAGCTTGCTGCTGGATACGCTGCCCATGCTGGGCAACGCTCTGCTGCTTCTGCTTCTTCTGCTTCTT  
 CATCTTCGGCATCGTCGGCTCCAGCTGTGGGCGAGGCTGCTTCGGAACCGATGCTTCTACCTGAGAATTTCAAGCTCC  
 CCTGAGCGTGGACCTGGAGCGCTATTACACAGACAGAAACGAGGATGAGAGCCCTTCACTGCTCCAGCAGCGGAG  
 AACGGCATACGGTCTCTCAGAAAGCGTCCGACGCTGCGCGGGGACGCGGGCGGTGGCCACCTTGCGGCTTGAGCATATGA  
 GGCTCAACAGCTCCAGCAACACCACTGTGTCACTGGAAACGAGTACTACCAACATGCTCAGCGGGGAGCACAAAC  
 CCTTCAAGGGCGCATCAACTTGTGACACATTTGGCATTTGCTGGATGCCATCTTCCAGCTCATCAGCTTGAGGGCTGG  
 TCGCATCATGTACTTTGTATGGATGCTCATTTCTTCAACTTTCATCTACTCATCTCCTCATCATCTGTTGGGCTCT  
 CTTCTTCATGATCAACCTGTGCTGCTGTGGTATGCCACGCACTTCAGAGAACGAGCAGCGGAAAGCGCAGTGTGTC  
 GGGAGCAGGCTGTGGGCTTCTGTCCAAACGCCAGCACCTGGTGTAGCTTCTCTGAGCCCGGCGAGCTGTATGAGGAGCTG  
 CTCAACTGCTGTGTACATCTCTTCTGAAGCAGCCGCGAGGCTGGCTCAGGTTCTGCGGACGAGTGCTGTGGGGTTGG  
 GCTGCTCAGCAGCCAGCACCCCTCGGGGCCAGGAGACCCAGCCACGACAGCTGTCTCTGCTCCACCGCGCCTAT  
 CCGTCCACCACTGGTGACCCACCAACCAACCATCACCACTACCACTGGGCAATGGGACCTCAGGCGCCCCCGG  
 GCCAGCCCGAGATCCAGGACAGGGATGCCAATGGTCCCGCGGCTCATGCTGCCACCACTCCCTGACGCTGTGCCCTCTC  
 CGGGGCCCCCTGGTGCGCAGAGTCTGTGCACAGCTTCTACCATGCCGATGCCACTAGAGCCAGTCCGCTGCCAGG  
 CGCCCCCTCCAGGTCCCCATCTGAGGCTCCGGCAGGACTGTGGGCGAGCGGGAAGGTATCCCCACCTGTACACACAGC  
 CCTCCACCGGAGCGCTGAAGGAGAAGGCACTAGTAGAGGTGGCTGCCAGCTCTGGGCCCCAACCCCTCACCAGCCTCAA  
 CATCCACCCCGGCCCTACAGCTCCATGCAACAAGCTGCTGGAGACACAGAGTACAGGTGCCCTGCCAAAGCTCTTGCAAGA  
 TCTCCAGCCTTGCTTGAAGCAGACAGTGGAGCTGTGGTCAGACAGCTGCCCTACTGTGCCCGGGCGGGGCGAGG  
 GAGGTGGAGCTGCCGACCGTGAATGCCGTGACTCAGACAGCGAGGCAGTTATGAGTTACACAGAGATGCCAGCACAG  
 CGACTCCGGGACCCCAAGCGCGCGGCAACGGAGCTGGGCCAGATGACAGAGCCAGCTCTGTGCTGGCTCTCTGGA  
 GCTAATCTGTGTACACTCTCCGAAGATTGTGGACAGCAAGTACTTTGGCGGGGAATCATGTACCGGCATCTGTGTCAAC  
 AACTCAGCATGGGCATCGAATACCAAGAGCAGCCGAGGAGCTTACCAAGCCCTAGAAATCAGCAACATCGTCTTCAAC  
 CAGCCTCTTTGCCCTGGAGATGTGCTGTAAGCTGTCTTGTATGTTGCCCTTTGGCTACATCAAGAATCCCTACACACTT  
 TCGATGGTGTCAATTGGTTCATCAGCGTGTGGGAGATCGTGGCGACAGAGGGGGCGGCTGTGGTGTCTGGCAACTTC  
 CGCTGATGCGTGTCTGGAAGCTGTGTGCGCTTCTGCGCGCGCTGCGAGCGAGCTGGTGGTGTCTCATGAAGACATGGA  
 CAACCTGGCCACTTCTGTGATGCTTATGCTTTCATCTTCATCTTCAGCATGCTGGGCATGCTTCTCTCGGCTGCA  
 AGTTTGGCTCTGAGCGGGATGGGGACACCTCGGACAGCCGAAGAATTTGACTCTTGCTCTGGGCCATGCTCATGCTC  
 TTTAGATCTTGACCCAGGAGGACTGGAACAAAGTCTCTACAAATGGTATGGGCTCCAGTCTGCTTGGGCGGCCCTTTA  
 TTTACTTGCCTCATGACTCTCGGCAACTACGTGCTCTTCAATTTGCTGTGCGCATCTGTGTGGAGGGCTTTCAGGCGG  
 AGGGAGATGCCAACAGTCCGAATCAGAGCGGATTTCTTCTCACCCAGCTGGATGGTGTGAGGGGACAGAGGAAGTGC  
 TTGGCTTGGTGTGCTTGGGAGAGCACCCGAGCTGCGGAAGAGCCCTGCTGCGCCTCTCATATCCACAGCGGCCAC  
 ACCATCTGCTGCGCCAAAGCACACAGCAGCGGCTGCGCGAGGCGCTGGGCTGCTGCTGCGCGCACACAGCAGG  
 GGTGCGCAGAGCTGGGGCGGCCACAGAGATGAAGTACCGGCCAGCGCCCGAGCTCTCCGACAGCCCTGGAGCGCT  
 CGAGCAGCTGGACAGAGCGCTCCAGCCGGAACAGCCTCGGCCGTGCACCCAGCCTGAAGCGGAGAGGCCAAGTGG  
 AGAGCGCGCTGCTGCTTTGTTCGGGAAGAGGCCAGGAGAGCCAGGATGAAGAGAGGCTCAGAGAGAGGCGGCGAGCC  
 CTCGCGGCGAGTGACCTTCCGCAAGGGGCTTCCGGAGCGGAGGCCAAGAGTTCCTTTGACCTGCCACACACTGACG  
 GTCCAGGGCTCATCGACTCTGAGTGGCGAGGCTGTGCTGACACAGGATGCAATGCAAGTTCGGCTTCAGG  
 GCGCTTGGCCCGGCTCTGCGGCTGATGACCCCCCATGTGATGGGATGACGCGGATGACGAGGGCAACTGT

Figure 3B (SEQ ID NO:52)

MDEEEDGAGAEESGQPRSFMRNLNDLSGAGRPGPGSAEKDPGSA  
DSEAEGLPYPALAPVVFYLSQDSRPSWCLRTVCNPWFERISMLVILLNCVTLGMFR  
PCEDIACDSQRCRILQAFDDFIFAFFAVEMVVKMVALGIFGKKCYLGDWTWNRLDFFIV  
IAGMLEYSLDLQNVSFSAVRTVRVLRPLRAINRVPSMRILVTLTLLDTLPMGLGNVLLLC  
FFVFFIFGIVGVQLWAGLLRNRCFLPENFSLPLSVDLERYQTENEDESPPFICSQPRE  
NGMRSCRSVPTLRGDGGGGPPCGLDYEAYNSSSNTTCVNWNQYYTNC SAGEHNPFGKA  
INFDNIGYAWIAIFQVITLEGWVDIMYFVMDAHSFYNFYIFILLIIVGSFFMINLCLV  
VIATQPSSETKQRESQLMREQVRFLSNASTLASFSPEGSCEYELLKYLVIYLRKAARR  
LAQVSRAGVRVGLLSSAPLGGQETQPPSSCSRSHRRLSVHHLVHHHHHHHHHHYHLG  
NGTLRAPRASPEIQDRDANGSRRLMLPPSPALSGAPPGGAESVHSFYHADCHLEPV  
RCQAPPPRSPSEASGRTVGSGKVYPTVHTSPPPETLKEKALVEVAASSGPPTLTSINI  
PPGPYSMHKLETTQSTGACQSSCKISSPCLKADSGACGPDSCPYCARAGAGEVELAD  
REMPDSDSEAVYEFTQDAQHSDLRDPHSRRQRSLGPD AEPSSVLAFWRRLICDTFRKIV  
DSKYFGRGIMIALVNTLSMGIEYHEQPEELTNALEISNIVFTSLFALEMLLKLVLYG  
PFGYIKNPYNI FDGVIIVVISVWEIVGQGGGLSVLRTFRLMRVLKLVRFPLALQRQLV  
VLMKTMONVATFCMLLMLFIFIFSILGMHLPGCKFASERDGTLPDRKNFDSLLWAIV  
TVFQILTQEDWNVLYNGMASTSSWAALYFIALMTFGNVVLFNLLVAILVEGFQAEGB  
ANKSESEDFPSPSLDQDGRKKCLALVSLGEHPDLRKSLPPLIITATPMSLPKS  
TETGLGEALGPASRRTSSSGSAEPGAHEMKSPPSARSSPHSPWSAASSWTSRRSSRN  
SLGRAPLSKRSPSGERRSLSGEGQESQDEEESSEERASPAGSDHHRHGLEREAK  
SSFDLPDTLQVPLHRTASGRGSASEHQDCNGKSASGRALARALRPDDPPLDGDADDE  
GNL

APOB CpG ISLAND (SEO ID NO:105)

CACNA1G CpG ISLAND (SEO ID NO:106)

[illegible]

FIGURE 4B

CDX2 CpG Island (SEQ ID NO:107)

ctcgttaatcacggaagccgccggcctggggctccgcacgccagcctgtcggggtcttccccgcctctgcagcctagtgggaaggaggt  
gggaggaagaaggaaaggaggaggaggaggagcaggccaggaggaggaccgcctcggaggcagagaagaccgcgagg  
agccagcggagcaccggggctggggcgcgagccaccgcgctcctcagagtcacctcgccttctcgtgcccccccgcaagcctc  
cagcgtcgggtcccgagcagcatggtaggtctgctcccggctccctgccaccatgtacgtgagcta

EGFR CpG Island (SEQ ID NO:108)

gtccgggggacccgggtccagaggggcagtgctgggaacgccctctcggaaattaactctcagggcaccgctccccctccatgcgc  
gcccactcccgcggagactagggtcccgcgggggccaccgtgtccaccgctcgcggccgctggccttgggtccccctgctggttct  
ctctctctctctcgatttctctctctctctgctctccgatccctctccgcgcctgtgtcctctctctccgcctcgcctccgcgcctc  
ggcccgcgcgagctagactccgggcagcccccgcgagcgcggccgcagcagcctctccccgcacgggtgtagagcggccgcc  
gcggcaggggcgccggagtcccgagctagccccgcggccgccggcccccagaccggagcagagggccactctgctgcgtccgccg  
agtcccccgcctcgccccaaccgcacaaaccaccgcgcacggccccctgactccgtccagtattgatcgggagagccggagcagctctt  
cggggagcagcgtatgcacccctccgggacggccggggcagcgcctcgtggcgctgctgctgcgtctgcccGggcgagtcgggctctg  
Gaggaaaagaaggtaaggggcgtgtctcgcggcctccccgccggccccggatcgcggccggagccccgcagccccccaaccgcacc  
gcgcaccggcttcgcccgcgccccgccctgtcttctgtttcttgagatcacgtgcggccggaccgggaccgcgggagggaacggg  
acgtttctgtttctgcggcgaggagtctggggcgggcgaggaggaagacgcgtgggacaccggcgctcagggccagcgggggaacgg  
ccggccgggacctccggcgccccgaaccgctcccaactttcttccctcactttccccgccagctgcgcaggatcggcgctcagtgggcgaa  
agccgggtgctggtggggcgctggggcgccgggtcccgacgggctccccgcgtgtcttccaggggcgacgggggtcctcgcgcgc  
accggaggccgctgcccaccgccgagactcctgtttagggaagctgagggaaggaacccaaaatacacgctccgctcggaccgccg  
cgggacaggcgccgttctgagagagacctccccgcctccgcgctccgcgcaggtctcaaaagtgaagccggcgcccggacgctggcccc  
ggccccctccagggtccccgcgactctgttccccagtgtggagtcgcagcctcgaacctgggagctgggagaactcgtctaccaccactg  
cggctcccgaggagggtggtgtcggcggttagtttctcgttgcaaaaggcaggtgggtccgaccgcccttggcgcgagac  
ccggcgccgtcggcctcggcggtcgcctcgtcttgctatccaagagtgccccccactccgggaccccgactccctccgcgcgcgc  
gccgaagccccaggctctctctgatggcgccctcgcggagacgtccgggtctgtccacctcgagcccttcggtcgcgctgggttc  
gggttgagcgggagcgcgtgtccggccactgcaggggggatcgcgggactctgagcgggaagccccg

FIGURE 4C  
FBNI CpG Island (SEQ ID NO:109)

agagccgctgctcgaagtggcctctcgacaccagggcaagtggggcgccagagccctctctcggctcgccacagcagcctctgcccgggctccgg  
cctcgacgcgctccagcctctagcctcccgccctccggcctgctgctgagtgctccggcggaagggcgagggagcgcgctaacccggagggcgccggc  
agcggggagctgtttctctcggccaggcctccggcgaaacgctccagcgcgcattctgtgcagtggaacacgtttctgctcggtagggcct  
cacctatcgcgggagagtgtaattctcgaftaaacctgcagccgcagagcgggctaaaaccgtactccacctcttccattctccctcccaacct  
aagacaaaagtccaggccggggcagggacctgacacacctgctcctctccactgctgctaaactcgcgagcgaagggccccgcacccgagcggagg  
ctgcaaaaggggagtggaaggagagtgatggatggggccgggggggtgggtgggtgagtgaggcgacgaaggaggggggtgctatttttttttttt  
ttaaaaaagtattctctcgcgaacacgctgcggcgacgatacttgaaaggtggggaaaggagggggctgcgggagccgcggcagagactgtg  
ggtgccacaaggcgagcaggaagccacagctgGgacagctgcgagcgggagccgagcagtggtgctgtagcggccacgactgggagcagccgcccgc  
cctctcgggagtcggaagccgctctccagtggtggtgcagccgggggtccgacggggggtggggggccacccggggctggagctgcggccacgga  
ggcttttgcgttggccggnnngaggcgagggacaggagctgggggtgaggggctgctccgggaacgtccaaactgggncgctggacccctccctgct  
gacagcttctnccggggcttctgtgctggcggcggcgcgtcagatgttcggggggggtgctatcccccagtgccggcgagcggcggcgtctt  
ccagctggcgagaggcgaggctgagggagtggtggcggtcagagcgcgcacatctgctccgtaaaaaataaacccagagagctgcgc  
cgggggcttgagaccgtgggagatgggtacttttgcgcggcgtcttctgcccggggccgggagcgagaggttgccggggctgctgcgcgggg  
ggctggcttccagcagctgtggaaccaagctctccttaaccaaataactgcgcacagcgccggcggaacnggtggcttgggaatgggggacc  
ggagcttcacgacccagtcgctgaaagtctcccgctcggggattgtctgtgtgagctggcagcgcccgctgaagggtgggagcagcgctc  
gggaaggcggggagggagccggccggggggcagggcgccggggatagcgggaaccccggcgccgctggctgccttcaaggcgacggcgccg  
cagaccgagcccgccggcgccggaagagcgccggcggaagcggcggtggcggtcgacatcagctgcgagggcgctgctggagatcgccctgggatt  
accgtgcttttagcgtctacacagagccatggggcgagcggcaatttggaggtcgggaacgtgaaggaaaccagagccaactggggccaagagaaga  
ggcggtggagacacgagcgccttaagggtgaaaggaaacgggttccct

GPR37 (SEQ ID NO:110)

Tcccgcgccgacccgccctagcccgccgctcggggacctgtcaggtgttctgacagctggggaattaaactgtcccgccatccctagcctcag  
ccgcgcaggtctcgcgctccgcttctcctccagctcctccgagtggaagccgctacaaatggcttgaatgaacgtgtgtgtgtgtttagtgatg  
gtgaaccaccaggggatccgtctcccaacaaaccagatctctccgaggaaggagcgaaggagtgaggagggcaacagagccgagagtgagctt  
cgcggcgccgcgcagcggctggagagcgggggctgagggccggccacctcccttccggccgcgcactgctgcccggcggtgttcaggga  
ccacctctccgtccgctgagccgctgtggtcagtgactagctcccgctcagctggcactgtcaccacagcagcggcgccctcttctccctctt  
ccccagatttcttcttggggcgcaacccgttcagcagcctgtcttcgcccgtctgtaacatttgagctgaggaagaagcaatttggcagtgccgc  
gggggtggaatccgcttctcctcggcagcagtagctcgaagtgcgtgggtgtaggtggggcaagatttccggccgacatagcgtctcctggag  
tgtttgcaacgtgtttccagagagcgtgggagcgggggtgtgactgcgagtgctgggggggggggactgttttttcttctcagacctcggcttga  
actgtgatcaacgctgtcga

HSPA6 CpG Island (SEQ ID NO:111)

tgattcgcagtggttaacatctatctcgttctcctccgtggctctcagcggccctccaaggcagcccgagcccgctgctcctcaggagctctccac  
agcccggggaggaacttgctctaaagtgtcttcttcagctctgcacaaacccgcgctctcagagccagcggaggagctagaacctctccgc  
gtttcttccagcagcctgagtcagaggcggtcgttgccttgcaagtggcccgccagccttctcgtctccagcagcgatccgccgaaccttctccgc  
ggctcagccgcgctgcgcgcgggctgactcagcccgggcgccggcgggcgaggctctcagctggggcggaagtggcggaagggttcggc  
cggcggggtcggggaggtgcaaaaggatgaaaaagccgtggagcggagctgagacgatccggccggcgctgcggcgagaaacccgagggagga  
cctcactgtcagcgccctcgcgcggcgccgacagcctcctggtgcctcagcatcgcagaa

IOGAP2 CpG Island (SEQ ID NO:112)

IOGAP2 CpG Island (SEQ ID NO:112)

Agaggttcacttttacttcagtgtagcgcgcgcggcgccgtgctgctcctggcgagagagaccgaggggagtgggtcgcagatcttcgg  
gcgcgctaggcgaaatcgcgagagagcgggatccgagcgcgccggcgggggcgagagccgcgagcctggccagcgagggtagcc  
gcggggggcgcgccccgcgcggcgccccggagacgcgcaggatgccacaggaagatcgcttcgctgcagagaccccgctatgg  
ctctatggcgacagtga

KL CpG Island (SEQ ID NO:113)

[illegible]

PAR2 CpG Island (SEQ ID NO:114)

Cccggggcggtggcctcccgaggtgagtagctgctcttcggttccctgaacctaaccgcccctggggagggcgcgagcagaggt  
ccgattcggggcaggtgagaggctgacttctctggtgcgtccagtgagctctgagtttcgaatcgcgcgggcggttccccgcgcgc  
ccggcgctcgggcctccaggagtagcgaggccccagcgcgcggtgctgctggggggccgcatctgc



SDC1 CpG Island (SEQ ID NO:118)

SDC4 CpG Island (SEQ ID NO:119)

Agtaggagaccggcggcgctcggcgaggcggggtccctgggggtttcaacatccgcggcgggcgagtgccccgaggcgctcgcttc  
actgggaafftcggcggggttcggcgggcgggcgaggcgggcgggcgaggcggttagcgagccctataaagaggggtgagc  
cgccccggcgggcgacatcgcgagcatctcgcgctcttcagctcggcggttcgagtcggcccccgctctgtgctgctgctgtg  
cttcgtaggcgggagtcgccgagtcgggtggtcttggagggttccgggctggggcggaagcggggcgcgagccgggtgcctcttgtt  
cgtcgagcgtggtagggggggggcgagatcggggagtcagctccccacccagcgaggcgggcggaacttftgggaaacttgc  
gttcggggctacggcgagctccgggagcttcgagtcgacgcgctgcggccctcgtggtgtcttcgcctcccgccgctcagacc  
cgccggggctacgggctcgttagtgactaacgccggtgtcaactcttaacctcaacacctgtcccttcctcggtgacctggggcagg  
cttggagcgtgaatccccctctcgtctcggcgccagagcagacagcgttaggattccgagatggccctcgaggctgggggtctgc  
gtactacgcagggggggggttttagggctggcgagcc



FIGURE 5

MINT31 (SEQ ID NO:120)

|            |             |            |            |            |            |
|------------|-------------|------------|------------|------------|------------|
| CCCGGGGCCT | CTATCCTGGC  | GGGAAGGGCA | GGCCGACCCG | GCAGACTGCG | GCCTCTCGGG |
| AGGGAAGAAG | GTGTCAGACG  | CGCGGAGCAA | CCATAAATAG | CCCCCCTTTC | CCAGAAGACG |
| GCACGCGGTT | CAAGACTCAG  | GCGCCGCATA | CTCAGAATGA | GAGCAGAGAC | TCCCGCCAGG |
| AAAAAAGGGC | ACTTAGGGGA  | TCTGCTCATT | AACATGAAAT | GCAAATGAGC | CCGCCCGGCC |
| TCATTACAC  | AACTCTGTGC  | ATGGATTTCG | CGAAAGGGCA | ACCAGGGAGA | CGACGGCGCA |
| GCAGCCACTC | TGCCACTTCC  | CCCATCCCCT | CCCCCCCATC | GGCCGGGGCG | GGAAGTGAGA |
| CGACCCCAAC | CCTCTGCGGC  | GGCGGGAGGT | GCGCGGGGGC | TGCGTGGGTG | GTGCAGCCTT |
| AGGGGAGTGA | ACAACGCCCCA | GGGGTGATGG | CCTCAGCAAA | GTGAGGGGTG | GTGATGGAGG |
| TCATCCGACC | CATCCCGCCG  | CCTCTCCGCA | GTGGCGCAAG | CGCCCCAAAA | TCTCCGGAGA |
| NGGAACTGAG | TGACCCACTA  | GGTTCCGCCG | TGTCTACCTC | TCGCAGATGT | TGGGGAAGTG |
| CTTCCCGGCG | TCTAATCCTC  | GCTGTTCCCC | CCTCCACCCG | CGCCCAGCAC | ACCCGCGGCG |
| CTCCGCTCCC | GGG         |            |            |            |            |

DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name.

I believe that I am an original, first and only inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled CACA1G POLYNUCLEOTIDE POLYPEPTIDE AND METHODS OF USE THEREFOR, the specification of which

  X   is attached hereto.

  X   was filed on September 15, 1999, (Attorney Docket No. JHU1590)

as U.S. Application Serial No. \_\_\_\_\_

and was amended on \_\_\_\_\_

if applicable (the "Application").

**I hereby authorize and request insertion of the application serial number of the Application when officially known.**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability of the subject matter of the Application as defined in Title 37, Code of Federal Regulations ("C.F.R."), § 1.56.

With respect to the Application, I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

With respect to the Application, I hereby claim the benefit under 35 U.S.C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability of the subject matter of the Application as defined in Title 37, C.F.R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of the Application:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Jean-Pierre Issa

Inventor's signature: \_\_\_\_\_

Date: \_\_\_\_\_

Residence: Timonium, MD

Citizenship: Lebanon

**Post Office Address:** 100 Welford Road  
Timonium, MD 21231